{
  "model": "gpt-5.2",
  "taskId": "tumor-vaccine-ici",
  "runIndex": 3,
  "result": {
    "text": "- [x] `output/study_overview.json`\n- [x] `output/quantitative_findings.json`\n- [x] `output/claim_audit.json`\n- [x] `output/public_summary.json`",
    "thoughts": "",
    "steps": [
      {
        "step": 1,
        "modelVersion": "gpt-5.2-2025-12-11",
        "text": "[tool-call]\\n{\n  \"id\": \"fc_078df658a1e25c9f00699071fbbeb0819eb251b1966f65e3f1\",\n  \"type\": \"function_call\",\n  \"status\": \"completed\",\n  \"arguments\": \"{\\\"file_path\\\":\\\"TASK.md\\\",\\\"offset\\\":0,\\\"limit\\\":400}\",\n  \"call_id\": \"call_MYlvZjkoMaCZoJ3ORoC4nxiH\",\n  \"name\": \"read_file\",\n  \"parsed_arguments\": null\n}\\n",
        "toolCalls": [
          {
            "toolName": "read_file",
            "input": {
              "file_path": "TASK.md",
              "offset": 0,
              "limit": 400
            },
            "output": "L1: # Agent Task\nL2: \nL3: Task id: tumor-vaccine-ici\nL4: Task title: mRNA tumor sensitization for checkpoint blockade\nL5: Reference paper: SARS-CoV-2 mRNA vaccines sensitize tumours to immune checkpoint blockade\nL6: Reference URL: https://www.nature.com/articles/s41586-025-09006-8\nL7: \nL8: ## Objective\nL9: Read the report and produce all required JSON outputs that satisfy their schemas.\nL10: \nL11: ## Inputs On Disk\nL12: - Report: `input/report.md`\nL13: - Schemas: in `schemas/`\nL14: \nL15: ## Required Outputs\nL16: - `output/study_overview.json` (schema: `schemas/study_overview.schema.json`)\nL17: - `output/quantitative_findings.json` (schema: `schemas/quantitative_findings.schema.json`)\nL18: - `output/claim_audit.json` (schema: `schemas/claim_audit.schema.json`)\nL19: - `output/public_summary.json` (schema: `schemas/public_summary.schema.json`)\nL20: \nL21: ## Constraints\nL22: - Do not invent source facts; derive calculations only from values in the report.\nL23: - Use line refs as `L<number>` where required.\nL24: - Where quotes are required, copy exact report snippets.\nL25: - For calculation outputs, line_refs must include every report line used for equations, constants, and numeric substitutions.\nL26: - Use relative paths only.\nL27: - Never use absolute paths.\nL28: - Never use `..` in paths.\nL29: - Write valid JSON only.\nL30: \nL31: ## Completion\nL32: Respond with a checklist of written output files.\nL33: After the checklist, stop. Do not call more tools.",
            "callId": "call_MYlvZjkoMaCZoJ3ORoC4nxiH"
          }
        ],
        "usage": {
          "promptTokens": 561,
          "cachedTokens": 0,
          "responseTokens": 30,
          "thinkingTokens": 30,
          "totalTokens": 621
        },
        "costUsd": 0.00182175
      },
      {
        "step": 2,
        "modelVersion": "gpt-5.2-2025-12-11",
        "text": "[tool-call]\\n{\n  \"id\": \"fc_078df658a1e25c9f00699071feec74819eb6834ea0709129e7\",\n  \"type\": \"function_call\",\n  \"status\": \"completed\",\n  \"arguments\": \"{\\\"dir_path\\\":\\\"schemas\\\",\\\"ignore\\\":null,\\\"file_filtering_options\\\":{\\\"respect_git_ignore\\\":null,\\\"respect_gemini_ignore\\\":null}}\",\n  \"call_id\": \"call_EO2cum8s5eteqdCIW752ShCA\",\n  \"name\": \"list_directory\",\n  \"parsed_arguments\": null\n}\\n[tool-call]\\n{\n  \"id\": \"fc_078df658a1e25c9f00699071feec84819eaa9bc137182e6abe\",\n  \"type\": \"function_call\",\n  \"status\": \"completed\",\n  \"arguments\": \"{\\\"file_path\\\":\\\"input/report.md\\\",\\\"offset\\\":0,\\\"limit\\\":400}\",\n  \"call_id\": \"call_ayXbbIREof2YEEMmDT7v60BN\",\n  \"name\": \"read_file\",\n  \"parsed_arguments\": null\n}\\n[tool-call]\\n{\n  \"id\": \"fc_078df658a1e25c9f00699071feec8c819e8d5b339817a984f1\",\n  \"type\": \"function_call\",\n  \"status\": \"completed\",\n  \"arguments\": \"{\\\"pattern\\\":\\\"*.schema.json\\\",\\\"dir_path\\\":\\\"schemas\\\",\\\"case_sensitive\\\":true,\\\"respect_git_ignore\\\":null,\\\"respect_gemini_ignore\\\":null}\",\n  \"call_id\": \"call_17vm67bGd2OLd1RsclvXCj0l\",\n  \"name\": \"glob\",\n  \"parsed_arguments\": null\n}\\n",
        "toolCalls": [
          {
            "toolName": "list_directory",
            "input": {
              "dir_path": "schemas",
              "ignore": null,
              "file_filtering_options": {
                "respect_git_ignore": null,
                "respect_gemini_ignore": null
              }
            },
            "output": "claim_audit.schema.json\npublic_summary.schema.json\nquantitative_findings.schema.json\nstudy_overview.schema.json",
            "callId": "call_EO2cum8s5eteqdCIW752ShCA"
          },
          {
            "toolName": "read_file",
            "input": {
              "file_path": "input/report.md",
              "offset": 0,
              "limit": 400
            },
            "output": "L1: # Structured Paper Report: Tumor Sensitization by mRNA Vaccination\nL2: \nL3: ## Citation\nL4: - Title: SARS-CoV-2 mRNA vaccines sensitize tumours to immune checkpoint blockade\nL5: - Journal: Nature\nL6: - Year: 2025\nL7: - DOI: 10.1038/s41586-025-09006-8\nL8: - Source URL: https://www.nature.com/articles/s41586-025-09006-8\nL9: \nL10: ## One-Paragraph Context\nL11: Immune checkpoint inhibitors (ICIs) can produce durable responses in some cancers, but many tumors remain non-responsive due to weak antigen presentation or poor immune priming. The paper investigates whether intratumoral delivery of an mRNA vaccine can create an interferon-rich inflammatory state that improves sensitivity to anti-PD-L1 therapy.\nL12: \nL13: ## Study Design Snapshot\nL14: - Preclinical arm: multiple murine tumor models with intratumoral mRNA vaccine and anti-PD-L1 combinations.\nL15: - Translational arm: a retrospective cohort of metastatic patients receiving ICI treatment, compared by prior SARS-CoV-2 mRNA vaccination status.\nL16: - Mechanistic probes: immunopeptidomics, transcriptomics, and perturbation controls (including IFNAR1 blockade and non-mRNA particle controls).\nL17: \nL18: ## Cohorts and Scenarios\nL19: 1. Mouse efficacy cohort (combination therapy): 78 tumor-bearing mice pooled across repeat experiments.\nL20: 2. Mouse control cohort (vaccine only, ICI only, and vehicle): 84 tumor-bearing mice pooled across matched controls.\nL21: 3. Human retrospective metastatic cohort: 130 patients total.\nL22: 4. Human vaccinated subgroup: 43 patients.\nL23: 5. Human unvaccinated subgroup: 87 patients.\nL24: \nL25: ## Quantitative Findings\nL26: | Metric | Vaccine/Combination Arm | Comparator | Interpretation |\nL27: |---|---:|---:|---|\nL28: | Fraction of tumor proteins represented in immunopeptidome | 62.3% | 37.3% | Broader antigen display after intratumoral mRNA vaccination |\nL29: | Fraction of proteins represented in MHC-I peptidome | 40.6% | 20.6% | Strong expansion of MHC-I-presented landscape |\nL30: | Retrospective human survival comparison p-value | p=0.01 | N/A | Vaccinated subgroup had improved survival under ICI treatment |\nL31: | Type I interferon response score (normalized units) | 3.1 | 1.0 | Marked induction after mRNA vaccination in tumors |\nL32: | PD-L1 expression fold-change in tumor tissue | 2.4x | 1.0x | Checkpoint axis became more targetable |\nL33: | Intratumoral CD8+ T-cell density fold-change | 1.8x | 1.0x | Increased immune infiltration with combination therapy |\nL34: \nL35: ## Controls and Null/Conditional Results\nL36: - Vaccine-only treatment did not produce durable tumor control in non-immunogenic models.\nL37: - ICI-only treatment had limited activity in low-immunogenic baseline settings.\nL38: - Lipid particle controls lacking mRNA did not reproduce the sensitization effect.\nL39: - Blocking type I interferon signaling with anti-IFNAR1 eliminated the observed sensitization benefit.\nL40: \nL41: ## Mechanistic Chain Proposed by Authors\nL42: 1. Intratumoral mRNA vaccination triggers local innate sensing and type I interferon signaling.\nL43: 2. Interferon-associated antigen processing and presentation pathways increase.\nL44: 3. A broader peptide repertoire appears on MHC-I, improving tumor visibility to T cells.\nL45: 4. PD-L1 pathway activity also increases, creating a rationale for combining with checkpoint blockade.\nL46: 5. Combined intervention improves tumor control in mice and aligns with better outcomes in the retrospective human cohort.\nL47: \nL48: ## Caveats and Threats to Validity\nL49: - The human analysis is retrospective and non-randomized; residual confounding is likely.\nL50: - Vaccination timing relative to ICI initiation varied across patients.\nL51: - Tumor-type mix and treatment-history heterogeneity limit direct causal interpretation.\nL52: - Mouse model effects may not map one-to-one to all human tumors.\nL53: - Some mechanistic readouts were strongest in specific model systems rather than uniformly across all tested settings.\nL54: \nL55: ## Practical Takeaway\nL56: The study supports a biologically coherent hypothesis that intratumoral mRNA vaccination can prime tumors for stronger ICI responses, but prospective randomized studies are required before clinical protocol changes are justified.",
            "callId": "call_ayXbbIREof2YEEMmDT7v60BN"
          },
          {
            "toolName": "glob",
            "input": {
              "pattern": "*.schema.json",
              "dir_path": "schemas",
              "case_sensitive": true,
              "respect_git_ignore": null,
              "respect_gemini_ignore": null
            },
            "output": "schemas/claim_audit.schema.json\nschemas/public_summary.schema.json\nschemas/quantitative_findings.schema.json\nschemas/study_overview.schema.json",
            "callId": "call_17vm67bGd2OLd1RsclvXCj0l"
          }
        ],
        "usage": {
          "promptTokens": 1043,
          "cachedTokens": 0,
          "responseTokens": 124,
          "thinkingTokens": 22,
          "totalTokens": 1189
        },
        "costUsd": 0.00386925
      },
      {
        "step": 3,
        "modelVersion": "gpt-5.2-2025-12-11",
        "text": "[tool-call]\\n{\n  \"id\": \"fc_078df658a1e25c9f00699072025b20819ea0acf09c0487c3cd\",\n  \"type\": \"function_call\",\n  \"status\": \"completed\",\n  \"arguments\": \"{\\\"file_path\\\":\\\"schemas/study_overview.schema.json\\\",\\\"offset\\\":0,\\\"limit\\\":400}\",\n  \"call_id\": \"call_b9v4GBhK8BK469B6qbi6lXYq\",\n  \"name\": \"read_file\",\n  \"parsed_arguments\": null\n}\\n[tool-call]\\n{\n  \"id\": \"fc_078df658a1e25c9f00699072025b28819e9dc16856d5f701a2\",\n  \"type\": \"function_call\",\n  \"status\": \"completed\",\n  \"arguments\": \"{\\\"file_path\\\":\\\"schemas/quantitative_findings.schema.json\\\",\\\"offset\\\":0,\\\"limit\\\":400}\",\n  \"call_id\": \"call_PsrraLFfg0NmJsoSiHUUnyaO\",\n  \"name\": \"read_file\",\n  \"parsed_arguments\": null\n}\\n[tool-call]\\n{\n  \"id\": \"fc_078df658a1e25c9f00699072025b30819ea2b1c52940b528a5\",\n  \"type\": \"function_call\",\n  \"status\": \"completed\",\n  \"arguments\": \"{\\\"file_path\\\":\\\"schemas/claim_audit.schema.json\\\",\\\"offset\\\":0,\\\"limit\\\":400}\",\n  \"call_id\": \"call_HgGpLBPnVBlDPyeZguWkCo58\",\n  \"name\": \"read_file\",\n  \"parsed_arguments\": null\n}\\n[tool-call]\\n{\n  \"id\": \"fc_078df658a1e25c9f00699072025b3c819ea579cbf2fcd76391\",\n  \"type\": \"function_call\",\n  \"status\": \"completed\",\n  \"arguments\": \"{\\\"file_path\\\":\\\"schemas/public_summary.schema.json\\\",\\\"offset\\\":0,\\\"limit\\\":400}\",\n  \"call_id\": \"call_u6loZ85Z0EMIv0zogVdMM5aS\",\n  \"name\": \"read_file\",\n  \"parsed_arguments\": null\n}\\n",
        "toolCalls": [
          {
            "toolName": "read_file",
            "input": {
              "file_path": "schemas/study_overview.schema.json",
              "offset": 0,
              "limit": 400
            },
            "output": "L1: {\nL2:   \"$schema\": \"http://json-schema.org/draft-07/schema#\",\nL3:   \"title\": \"schemas-study_overview\",\nL4:   \"type\": \"object\",\nL5:   \"properties\": {\nL6:     \"paper\": {\nL7:       \"type\": \"object\",\nL8:       \"properties\": {\nL9:         \"title\": {\nL10:           \"type\": \"string\",\nL11:           \"minLength\": 10\nL12:         },\nL13:         \"doi\": {\nL14:           \"type\": \"string\",\nL15:           \"pattern\": \"^10\\\\.\"\nL16:         },\nL17:         \"publication_year\": {\nL18:           \"type\": \"integer\",\nL19:           \"minimum\": 1900,\nL20:           \"maximum\": 2100\nL21:         },\nL22:         \"domain\": {\nL23:           \"type\": \"string\",\nL24:           \"enum\": [\nL25:             \"oncology-immunology\",\nL26:             \"exoplanet-atmospheres\",\nL27:             \"climate-science\",\nL28:             \"neuroscience\",\nL29:             \"other\"\nL30:           ]\nL31:         },\nL32:         \"study_type\": {\nL33:           \"type\": \"string\",\nL34:           \"enum\": [\nL35:             \"preclinical+retrospective\",\nL36:             \"observational-astronomy\",\nL37:             \"randomized-trial\",\nL38:             \"simulation\",\nL39:             \"mixed\"\nL40:           ]\nL41:         }\nL42:       },\nL43:       \"required\": [\nL44:         \"title\",\nL45:         \"doi\",\nL46:         \"publication_year\",\nL47:         \"domain\",\nL48:         \"study_type\"\nL49:       ],\nL50:       \"additionalProperties\": false\nL51:     },\nL52:     \"core_question\": {\nL53:       \"type\": \"string\",\nL54:       \"minLength\": 20\nL55:     },\nL56:     \"datasets_or_cohorts\": {\nL57:       \"type\": \"array\",\nL58:       \"items\": {\nL59:         \"type\": \"object\",\nL60:         \"properties\": {\nL61:           \"id\": {\nL62:             \"type\": \"string\",\nL63:             \"pattern\": \"^[a-z0-9-]+$\"\nL64:           },\nL65:           \"label\": {\nL66:             \"type\": \"string\",\nL67:             \"minLength\": 3\nL68:           },\nL69:           \"sample_size_or_observations\": {\nL70:             \"type\": \"string\",\nL71:             \"minLength\": 1\nL72:           },\nL73:           \"description\": {\nL74:             \"type\": \"string\",\nL75:             \"minLength\": 20\nL76:           }\nL77:         },\nL78:         \"required\": [\nL79:           \"id\",\nL80:           \"label\",\nL81:           \"sample_size_or_observations\",\nL82:           \"description\"\nL83:         ],\nL84:         \"additionalProperties\": false\nL85:       },\nL86:       \"minItems\": 2,\nL87:       \"maxItems\": 8\nL88:     },\nL89:     \"major_limitations\": {\nL90:       \"type\": \"array\",\nL91:       \"items\": {\nL92:         \"type\": \"string\",\nL93:         \"minLength\": 12\nL94:       },\nL95:       \"minItems\": 3,\nL96:       \"maxItems\": 8\nL97:     }\nL98:   },\nL99:   \"required\": [\nL100:     \"paper\",\nL101:     \"core_question\",\nL102:     \"datasets_or_cohorts\",\nL103:     \"major_limitations\"\nL104:   ],\nL105:   \"additionalProperties\": false\nL106: }",
            "callId": "call_b9v4GBhK8BK469B6qbi6lXYq"
          },
          {
            "toolName": "read_file",
            "input": {
              "file_path": "schemas/quantitative_findings.schema.json",
              "offset": 0,
              "limit": 400
            },
            "output": "L1: {\nL2:   \"$schema\": \"http://json-schema.org/draft-07/schema#\",\nL3:   \"title\": \"schemas-quantitative_findings\",\nL4:   \"type\": \"object\",\nL5:   \"properties\": {\nL6:     \"findings\": {\nL7:       \"type\": \"array\",\nL8:       \"items\": {\nL9:         \"type\": \"object\",\nL10:         \"properties\": {\nL11:           \"id\": {\nL12:             \"type\": \"string\",\nL13:             \"pattern\": \"^Q[0-9]{2}$\"\nL14:           },\nL15:           \"metric\": {\nL16:             \"type\": \"string\",\nL17:             \"minLength\": 6\nL18:           },\nL19:           \"value\": {\nL20:             \"type\": \"string\",\nL21:             \"minLength\": 1\nL22:           },\nL23:           \"comparator_or_baseline\": {\nL24:             \"type\": \"string\",\nL25:             \"minLength\": 1\nL26:           },\nL27:           \"interpretation\": {\nL28:             \"type\": \"string\",\nL29:             \"minLength\": 12\nL30:           },\nL31:           \"evidence_line_refs\": {\nL32:             \"type\": \"array\",\nL33:             \"items\": {\nL34:               \"type\": \"string\",\nL35:               \"pattern\": \"^L[1-9]\\\\d*$\"\nL36:             },\nL37:             \"minItems\": 1,\nL38:             \"maxItems\": 3\nL39:           }\nL40:         },\nL41:         \"required\": [\nL42:           \"id\",\nL43:           \"metric\",\nL44:           \"value\",\nL45:           \"comparator_or_baseline\",\nL46:           \"interpretation\",\nL47:           \"evidence_line_refs\"\nL48:         ],\nL49:         \"additionalProperties\": false\nL50:       },\nL51:       \"minItems\": 5,\nL52:       \"maxItems\": 14\nL53:     },\nL54:     \"controls_or_null_results\": {\nL55:       \"type\": \"array\",\nL56:       \"items\": {\nL57:         \"type\": \"object\",\nL58:         \"properties\": {\nL59:           \"statement\": {\nL60:             \"type\": \"string\",\nL61:             \"minLength\": 10\nL62:           },\nL63:           \"evidence_line_ref\": {\nL64:             \"$ref\": \"#/definitions/schemas-quantitative_findings/properties/findings/items/properties/evidence_line_refs/items\"\nL65:           }\nL66:         },\nL67:         \"required\": [\nL68:           \"statement\",\nL69:           \"evidence_line_ref\"\nL70:         ],\nL71:         \"additionalProperties\": false\nL72:       },\nL73:       \"minItems\": 2,\nL74:       \"maxItems\": 10\nL75:     }\nL76:   },\nL77:   \"required\": [\nL78:     \"findings\",\nL79:     \"controls_or_null_results\"\nL80:   ],\nL81:   \"additionalProperties\": false\nL82: }",
            "callId": "call_PsrraLFfg0NmJsoSiHUUnyaO"
          },
          {
            "toolName": "read_file",
            "input": {
              "file_path": "schemas/claim_audit.schema.json",
              "offset": 0,
              "limit": 400
            },
            "output": "L1: {\nL2:   \"$schema\": \"http://json-schema.org/draft-07/schema#\",\nL3:   \"title\": \"schemas-claim_audit\",\nL4:   \"type\": \"object\",\nL5:   \"properties\": {\nL6:     \"claims\": {\nL7:       \"type\": \"array\",\nL8:       \"items\": {\nL9:         \"type\": \"object\",\nL10:         \"properties\": {\nL11:           \"claim_id\": {\nL12:             \"type\": \"string\",\nL13:             \"pattern\": \"^C[0-9]{2}$\"\nL14:           },\nL15:           \"claim\": {\nL16:             \"type\": \"string\",\nL17:             \"minLength\": 20\nL18:           },\nL19:           \"strength\": {\nL20:             \"type\": \"string\",\nL21:             \"enum\": [\nL22:               \"strong\",\nL23:               \"moderate\",\nL24:               \"tentative\"\nL25:             ]\nL26:           },\nL27:           \"evidence\": {\nL28:             \"type\": \"array\",\nL29:             \"items\": {\nL30:               \"type\": \"object\",\nL31:               \"properties\": {\nL32:                 \"quote\": {\nL33:                   \"type\": \"string\",\nL34:                   \"minLength\": 10\nL35:                 },\nL36:                 \"line_ref\": {\nL37:                   \"type\": \"string\",\nL38:                   \"pattern\": \"^L[1-9]\\\\d*$\"\nL39:                 }\nL40:               },\nL41:               \"required\": [\nL42:                 \"quote\",\nL43:                 \"line_ref\"\nL44:               ],\nL45:               \"additionalProperties\": false\nL46:             },\nL47:             \"minItems\": 2,\nL48:             \"maxItems\": 3\nL49:           },\nL50:           \"caveat\": {\nL51:             \"type\": \"string\",\nL52:             \"minLength\": 20\nL53:           }\nL54:         },\nL55:         \"required\": [\nL56:           \"claim_id\",\nL57:           \"claim\",\nL58:           \"strength\",\nL59:           \"evidence\",\nL60:           \"caveat\"\nL61:         ],\nL62:         \"additionalProperties\": false\nL63:       },\nL64:       \"minItems\": 4,\nL65:       \"maxItems\": 10\nL66:     }\nL67:   },\nL68:   \"required\": [\nL69:     \"claims\"\nL70:   ],\nL71:   \"additionalProperties\": false\nL72: }",
            "callId": "call_HgGpLBPnVBlDPyeZguWkCo58"
          },
          {
            "toolName": "read_file",
            "input": {
              "file_path": "schemas/public_summary.schema.json",
              "offset": 0,
              "limit": 400
            },
            "output": "L1: {\nL2:   \"$schema\": \"http://json-schema.org/draft-07/schema#\",\nL3:   \"title\": \"schemas-public_summary\",\nL4:   \"type\": \"object\",\nL5:   \"properties\": {\nL6:     \"headline\": {\nL7:       \"type\": \"string\",\nL8:       \"minLength\": 20,\nL9:       \"maxLength\": 120\nL10:     },\nL11:     \"plain_language_summary\": {\nL12:       \"type\": \"string\",\nL13:       \"minLength\": 180,\nL14:       \"maxLength\": 1200\nL15:     },\nL16:     \"what_is_new\": {\nL17:       \"type\": \"array\",\nL18:       \"items\": {\nL19:         \"type\": \"string\",\nL20:         \"minLength\": 20\nL21:       },\nL22:       \"minItems\": 3,\nL23:       \"maxItems\": 3\nL24:     },\nL25:     \"why_caution_is_needed\": {\nL26:       \"type\": \"array\",\nL27:       \"items\": {\nL28:         \"type\": \"string\",\nL29:         \"minLength\": 20\nL30:       },\nL31:       \"minItems\": 3,\nL32:       \"maxItems\": 5\nL33:     },\nL34:     \"glossary\": {\nL35:       \"type\": \"array\",\nL36:       \"items\": {\nL37:         \"type\": \"object\",\nL38:         \"properties\": {\nL39:           \"term\": {\nL40:             \"type\": \"string\",\nL41:             \"minLength\": 2\nL42:           },\nL43:           \"definition\": {\nL44:             \"type\": \"string\",\nL45:             \"minLength\": 20,\nL46:             \"maxLength\": 220\nL47:           }\nL48:         },\nL49:         \"required\": [\nL50:           \"term\",\nL51:           \"definition\"\nL52:         ],\nL53:         \"additionalProperties\": false\nL54:       },\nL55:       \"minItems\": 4,\nL56:       \"maxItems\": 8\nL57:     },\nL58:     \"open_questions\": {\nL59:       \"type\": \"array\",\nL60:       \"items\": {\nL61:         \"type\": \"string\",\nL62:         \"minLength\": 20\nL63:       },\nL64:       \"minItems\": 3,\nL65:       \"maxItems\": 6\nL66:     }\nL67:   },\nL68:   \"required\": [\nL69:     \"headline\",\nL70:     \"plain_language_summary\",\nL71:     \"what_is_new\",\nL72:     \"why_caution_is_needed\",\nL73:     \"glossary\",\nL74:     \"open_questions\"\nL75:   ],\nL76:   \"additionalProperties\": false\nL77: }",
            "callId": "call_u6loZ85Z0EMIv0zogVdMM5aS"
          }
        ],
        "usage": {
          "promptTokens": 2334,
          "cachedTokens": 1024,
          "responseTokens": 137,
          "thinkingTokens": 15,
          "totalTokens": 2486
        },
        "costUsd": 0.0045997
      },
      {
        "step": 4,
        "modelVersion": "gpt-5.2-2025-12-11",
        "text": "[tool-call]\\n{\n  \"id\": \"fc_078df658a1e25c9f006990720aea70819e9081800dfae7b751\",\n  \"type\": \"function_call\",\n  \"status\": \"completed\",\n  \"arguments\": \"{\\\"dir_path\\\":\\\"output\\\",\\\"ignore\\\":null,\\\"file_filtering_options\\\":{\\\"respect_git_ignore\\\":null,\\\"respect_gemini_ignore\\\":null}}\",\n  \"call_id\": \"call_22rzCVjxc3oGyrDAHTN33qYQ\",\n  \"name\": \"list_directory\",\n  \"parsed_arguments\": null\n}\\n",
        "toolCalls": [
          {
            "toolName": "list_directory",
            "input": {
              "dir_path": "output",
              "ignore": null,
              "file_filtering_options": {
                "respect_git_ignore": null,
                "respect_gemini_ignore": null
              }
            },
            "output": "claim_audit.json\npublic_summary.json\nquantitative_findings.json\nstudy_overview.json",
            "callId": "call_22rzCVjxc3oGyrDAHTN33qYQ"
          }
        ],
        "usage": {
          "promptTokens": 5443,
          "cachedTokens": 0,
          "responseTokens": 44,
          "thinkingTokens": 459,
          "totalTokens": 5946
        },
        "costUsd": 0.01656725
      },
      {
        "step": 5,
        "modelVersion": "gpt-5.2-2025-12-11",
        "text": "[tool-call]\\n{\n  \"id\": \"fc_078df658a1e25c9f006990724f21bc819e936a9da109994d96\",\n  \"type\": \"function_call\",\n  \"status\": \"completed\",\n  \"arguments\": \"{\\\"file_path\\\":\\\"output/study_overview.json\\\",\\\"content\\\":\\\"{\\\\n  \\\\\\\"paper\\\\\\\": {\\\\n    \\\\\\\"title\\\\\\\": \\\\\\\"SARS-CoV-2 mRNA vaccines sensitize tumours to immune checkpoint blockade\\\\\\\",\\\\n    \\\\\\\"doi\\\\\\\": \\\\\\\"10.1038/s41586-025-09006-8\\\\\\\",\\\\n    \\\\\\\"publication_year\\\\\\\": 2025,\\\\n    \\\\\\\"domain\\\\\\\": \\\\\\\"oncology-immunology\\\\\\\",\\\\n    \\\\\\\"study_type\\\\\\\": \\\\\\\"preclinical+retrospective\\\\\\\"\\\\n  },\\\\n  \\\\\\\"core_question\\\\\\\": \\\\\\\"Whether intratumoral delivery of an mRNA vaccine can create an interferon-rich inflammatory state that improves sensitivity to anti-PD-L1 immune checkpoint therapy.\\\\\\\",\\\\n  \\\\\\\"datasets_or_cohorts\\\\\\\": [\\\\n    {\\\\n      \\\\\\\"id\\\\\\\": \\\\\\\"mouse-efficacy-combo\\\\\\\",\\\\n      \\\\\\\"label\\\\\\\": \\\\\\\"Mouse efficacy cohort (combination therapy)\\\\\\\",\\\\n      \\\\\\\"sample_size_or_observations\\\\\\\": \\\\\\\"78 tumor-bearing mice\\\\\\\",\\\\n      \\\\\\\"description\\\\\\\": \\\\\\\"Preclinical pooled mouse experiments testing intratumoral mRNA vaccine together with anti-PD-L1 combination therapy for tumor control.\\\\\\\" \\\\n    },\\\\n    {\\\\n      \\\\\\\"id\\\\\\\": \\\\\\\"mouse-matched-controls\\\\\\\",\\\\n      \\\\\\\"label\\\\\\\": \\\\\\\"Mouse control cohort (vaccine only, ICI only, vehicle)\\\\\\\",\\\\n      \\\\\\\"sample_size_or_observations\\\\\\\": \\\\\\\"84 tumor-bearing mice\\\\\\\",\\\\n      \\\\\\\"description\\\\\\\": \\\\\\\"Matched preclinical control arms in mice receiving vaccine-only, immune checkpoint inhibitor (ICI)-only, or vehicle control conditions.\\\\\\\" \\\\n    },\\\\n    {\\\\n      \\\\\\\"id\\\\\\\": \\\\\\\"human-retrospective-metastatic\\\\\\\",\\\\n      \\\\\\\"label\\\\\\\": \\\\\\\"Human retrospective metastatic cohort\\\\\\\",\\\\n      \\\\\\\"sample_size_or_observations\\\\\\\": \\\\\\\"130 patients\\\\\\\",\\\\n      \\\\\\\"description\\\\\\\": \\\\\\\"Translational retrospective cohort of metastatic patients receiving immune checkpoint inhibitor treatment, stratified by prior SARS-CoV-2 mRNA vaccination status.\\\\\\\" \\\\n    },\\\\n    {\\\\n      \\\\\\\"id\\\\\\\": \\\\\\\"human-vaccinated\\\\\\\",\\\\n      \\\\\\\"label\\\\\\\": \\\\\\\"Human vaccinated subgroup\\\\\\\",\\\\n      \\\\\\\"sample_size_or_observations\\\\\\\": \\\\\\\"43 patients\\\\\\\",\\\\n      \\\\\\\"description\\\\\\\": \\\\\\\"Subset of the retrospective metastatic cohort categorized as vaccinated prior to or around ICI treatment, used for survival comparison.\\\\\\\" \\\\n    },\\\\n    {\\\\n      \\\\\\\"id\\\\\\\": \\\\\\\"human-unvaccinated\\\\\\\",\\\\n      \\\\\\\"label\\\\\\\": \\\\\\\"Human unvaccinated subgroup\\\\\\\",\\\\n      \\\\\\\"sample_size_or_observations\\\\\\\": \\\\\\\"87 patients\\\\\\\",\\\\n      \\\\\\\"description\\\\\\\": \\\\\\\"Subset of the retrospective metastatic cohort categorized as unvaccinated, serving as the comparator group for survival under ICI treatment.\\\\\\\" \\\\n    }\\\\n  ],\\\\n  \\\\\\\"major_limitations\\\\\\\": [\\\\n    \\\\\\\"The human analysis is retrospective and non-randomized; residual confounding is likely.\\\\\\\",\\\\n    \\\\\\\"Vaccination timing relative to ICI initiation varied across patients.\\\\\\\",\\\\n    \\\\\\\"Tumor-type mix and treatment-history heterogeneity limit direct causal interpretation.\\\\\\\",\\\\n    \\\\\\\"Mouse model effects may not map one-to-one to all human tumors.\\\\\\\",\\\\n    \\\\\\\"Some mechanistic readouts were strongest in specific model systems rather than uniformly across all tested settings.\\\\\\\"\\\\n  ]\\\\n}\\\\n\\\"}\",\n  \"call_id\": \"call_ui1P3pP99T1My6lqYKrPXxJO\",\n  \"name\": \"write_file\",\n  \"parsed_arguments\": null\n}\\n[tool-call]\\n{\n  \"id\": \"fc_078df658a1e25c9f006990724f21cc819e9d788a59a72a8c80\",\n  \"type\": \"function_call\",\n  \"status\": \"completed\",\n  \"arguments\": \"{\\\"file_path\\\":\\\"output/quantitative_findings.json\\\",\\\"content\\\":\\\"{\\\\n  \\\\\\\"findings\\\\\\\": [\\\\n    {\\\\n      \\\\\\\"id\\\\\\\": \\\\\\\"Q01\\\\\\\",\\\\n      \\\\\\\"metric\\\\\\\": \\\\\\\"Fraction of tumor proteins represented in immunopeptidome\\\\\\\",\\\\n      \\\\\\\"value\\\\\\\": \\\\\\\"62.3%\\\\\\\",\\\\n      \\\\\\\"comparator_or_baseline\\\\\\\": \\\\\\\"37.3%\\\\\\\",\\\\n      \\\\\\\"interpretation\\\\\\\": \\\\\\\"Intratumoral mRNA vaccination was associated with broader antigen display in the immunopeptidome.\\\\\\\",\\\\n      \\\\\\\"evidence_line_refs\\\\\\\": [\\\\\\\"L28\\\\\\\"]\\\\n    },\\\\n    {\\\\n      \\\\\\\"id\\\\\\\": \\\\\\\"Q02\\\\\\\",\\\\n      \\\\\\\"metric\\\\\\\": \\\\\\\"Fraction of proteins represented in MHC-I peptidome\\\\\\\",\\\\n      \\\\\\\"value\\\\\\\": \\\\\\\"40.6%\\\\\\\",\\\\n      \\\\\\\"comparator_or_baseline\\\\\\\": \\\\\\\"20.6%\\\\\\\",\\\\n      \\\\\\\"interpretation\\\\\\\": \\\\\\\"The MHC-I-presented peptide landscape expanded substantially after the mRNA vaccination condition.\\\\\\\",\\\\n      \\\\\\\"evidence_line_refs\\\\\\\": [\\\\\\\"L29\\\\\\\"]\\\\n    },\\\\n    {\\\\n      \\\\\\\"id\\\\\\\": \\\\\\\"Q03\\\\\\\",\\\\n      \\\\\\\"metric\\\\\\\": \\\\\\\"Retrospective human survival comparison p-value under ICI\\\\\\\",\\\\n      \\\\\\\"value\\\\\\\": \\\\\\\"p=0.01\\\\\\\",\\\\n      \\\\\\\"comparator_or_baseline\\\\\\\": \\\\\\\"N/A\\\\\\\",\\\\n      \\\\\\\"interpretation\\\\\\\": \\\\\\\"In a retrospective comparison, vaccinated patients showed improved survival while on ICI treatment.\\\\\\\",\\\\n      \\\\\\\"evidence_line_refs\\\\\\\": [\\\\\\\"L30\\\\\\\"]\\\\n    },\\\\n    {\\\\n      \\\\\\\"id\\\\\\\": \\\\\\\"Q04\\\\\\\",\\\\n      \\\\\\\"metric\\\\\\\": \\\\\\\"Type I interferon response score (normalized units)\\\\\\\",\\\\n      \\\\\\\"value\\\\\\\": \\\\\\\"3.1\\\\\\\",\\\\n      \\\\\\\"comparator_or_baseline\\\\\\\": \\\\\\\"1.0\\\\\\\",\\\\n      \\\\\\\"interpretation\\\\\\\": \\\\\\\"Tumors showed a marked induction of a type I interferon response after intratumoral mRNA vaccination.\\\\\\\",\\\\n      \\\\\\\"evidence_line_refs\\\\\\\": [\\\\\\\"L31\\\\\\\"]\\\\n    },\\\\n    {\\\\n      \\\\\\\"id\\\\\\\": \\\\\\\"Q05\\\\\\\",\\\\n      \\\\\\\"metric\\\\\\\": \\\\\\\"PD-L1 expression fold-change in tumor tissue\\\\\\\",\\\\n      \\\\\\\"value\\\\\\\": \\\\\\\"2.4x\\\\\\\",\\\\n      \\\\\\\"comparator_or_baseline\\\\\\\": \\\\\\\"1.0x\\\\\\\",\\\\n      \\\\\\\"interpretation\\\\\\\": \\\\\\\"PD-L1 pathway activity increased in tumor tissue, supporting a rationale for checkpoint blockade combination.\\\\\\\",\\\\n      \\\\\\\"evidence_line_refs\\\\\\\": [\\\\\\\"L32\\\\\\\"]\\\\n    },\\\\n    {\\\\n      \\\\\\\"id\\\\\\\": \\\\\\\"Q06\\\\\\\",\\\\n      \\\\\\\"metric\\\\\\\": \\\\\\\"Intratumoral CD8+ T-cell density fold-change\\\\\\\",\\\\n      \\\\\\\"value\\\\\\\": \\\\\\\"1.8x\\\\\\\",\\\\n      \\\\\\\"comparator_or_baseline\\\\\\\": \\\\\\\"1.0x\\\\\\\",\\\\n      \\\\\\\"interpretation\\\\\\\": \\\\\\\"Combination therapy was associated with increased CD8+ T-cell infiltration in tumors.\\\\\\\",\\\\n      \\\\\\\"evidence_line_refs\\\\\\\": [\\\\\\\"L33\\\\\\\"]\\\\n    }\\\\n  ],\\\\n  \\\\\\\"controls_or_null_results\\\\\\\": [\\\\n    {\\\\n      \\\\\\\"statement\\\\\\\": \\\\\\\"Vaccine-only treatment did not produce durable tumor control in non-immunogenic models.\\\\\\\",\\\\n      \\\\\\\"evidence_line_ref\\\\\\\": \\\\\\\"L36\\\\\\\"\\\\n    },\\\\n    {\\\\n      \\\\\\\"statement\\\\\\\": \\\\\\\"ICI-only treatment had limited activity in low-immunogenic baseline settings.\\\\\\\",\\\\n      \\\\\\\"evidence_line_ref\\\\\\\": \\\\\\\"L37\\\\\\\"\\\\n    },\\\\n    {\\\\n      \\\\\\\"statement\\\\\\\": \\\\\\\"Lipid particle controls lacking mRNA did not reproduce the sensitization effect.\\\\\\\",\\\\n      \\\\\\\"evidence_line_ref\\\\\\\": \\\\\\\"L38\\\\\\\"\\\\n    },\\\\n    {\\\\n      \\\\\\\"statement\\\\\\\": \\\\\\\"Blocking type I interferon signaling with anti-IFNAR1 eliminated the observed sensitization benefit.\\\\\\\",\\\\n      \\\\\\\"evidence_line_ref\\\\\\\": \\\\\\\"L39\\\\\\\"\\\\n    }\\\\n  ]\\\\n}\\\\n\\\"}\",\n  \"call_id\": \"call_hqLD3PYqhdoqwZ4nauoI5YW5\",\n  \"name\": \"write_file\",\n  \"parsed_arguments\": null\n}\\n[tool-call]\\n{\n  \"id\": \"fc_078df658a1e25c9f006990724f21d4819ea9f801c2c37cc1d2\",\n  \"type\": \"function_call\",\n  \"status\": \"completed\",\n  \"arguments\": \"{\\\"file_path\\\":\\\"output/claim_audit.json\\\",\\\"content\\\":\\\"{\\\\n  \\\\\\\"claims\\\\\\\": [\\\\n    {\\\\n      \\\\\\\"claim_id\\\\\\\": \\\\\\\"C01\\\\\\\",\\\\n      \\\\\\\"claim\\\\\\\": \\\\\\\"Intratumoral mRNA vaccination induces a strong local type I interferon response in tumors.\\\\\\\",\\\\n      \\\\\\\"strength\\\\\\\": \\\\\\\"moderate\\\\\\\",\\\\n      \\\\\\\"evidence\\\\\\\": [\\\\n        {\\\\n          \\\\\\\"quote\\\\\\\": \\\\\\\"| Type I interferon response score (normalized units) | 3.1 | 1.0 | Marked induction after mRNA vaccination in tumors |\\\\\\\",\\\\n          \\\\\\\"line_ref\\\\\\\": \\\\\\\"L31\\\\\\\"\\\\n        },\\\\n        {\\\\n          \\\\\\\"quote\\\\\\\": \\\\\\\"Intratumoral mRNA vaccination triggers local innate sensing and type I interferon signaling.\\\\\\\",\\\\n          \\\\\\\"line_ref\\\\\\\": \\\\\\\"L42\\\\\\\"\\\\n        }\\\\n      ],\\\\n      \\\\\\\"caveat\\\\\\\": \\\\\\\"The report summarizes normalized scores, but does not specify timing, assay details, or variability across models in this excerpt.\\\\\\\"\\\\n    },\\\\n    {\\\\n      \\\\\\\"claim_id\\\\\\\": \\\\\\\"C02\\\\\\\",\\\\n      \\\\\\\"claim\\\\\\\": \\\\\\\"Intratumoral mRNA vaccination broadens tumor antigen presentation, including an expanded MHC-I peptidome.\\\\\\\",\\\\n      \\\\\\\"strength\\\\\\\": \\\\\\\"moderate\\\\\\\",\\\\n      \\\\\\\"evidence\\\\\\\": [\\\\n        {\\\\n          \\\\\\\"quote\\\\\\\": \\\\\\\"| Fraction of tumor proteins represented in immunopeptidome | 62.3% | 37.3% | Broader antigen display after intratumoral mRNA vaccination |\\\\\\\",\\\\n          \\\\\\\"line_ref\\\\\\\": \\\\\\\"L28\\\\\\\"\\\\n        },\\\\n        {\\\\n          \\\\\\\"quote\\\\\\\": \\\\\\\"| Fraction of proteins represented in MHC-I peptidome | 40.6% | 20.6% | Strong expansion of MHC-I-presented landscape |\\\\\\\",\\\\n          \\\\\\\"line_ref\\\\\\\": \\\\\\\"L29\\\\\\\"\\\\n        },\\\\n        {\\\\n          \\\\\\\"quote\\\\\\\": \\\\\\\"A broader peptide repertoire appears on MHC-I, improving tumor visibility to T cells.\\\\\\\",\\\\n          \\\\\\\"line_ref\\\\\\\": \\\\\\\"L44\\\\\\\"\\\\n        }\\\\n      ],\\\\n      \\\\\\\"caveat\\\\\\\": \\\\\\\"Some mechanistic readouts were strongest in specific model systems rather than uniformly across all tested settings.\\\\\\\"\\\\n    },\\\\n    {\\\\n      \\\\\\\"claim_id\\\\\\\": \\\\\\\"C03\\\\\\\",\\\\n      \\\\\\\"claim\\\\\\\": \\\\\\\"The intervention increases PD-L1 pathway activity in tumor tissue, supporting combination with checkpoint blockade.\\\\\\\",\\\\n      \\\\\\\"strength\\\\\\\": \\\\\\\"moderate\\\\\\\",\\\\n      \\\\\\\"evidence\\\\\\\": [\\\\n        {\\\\n          \\\\\\\"quote\\\\\\\": \\\\\\\"| PD-L1 expression fold-change in tumor tissue | 2.4x | 1.0x | Checkpoint axis became more targetable |\\\\\\\",\\\\n          \\\\\\\"line_ref\\\\\\\": \\\\\\\"L32\\\\\\\"\\\\n        },\\\\n        {\\\\n          \\\\\\\"quote\\\\\\\": \\\\\\\"PD-L1 pathway activity also increases, creating a rationale for combining with checkpoint blockade.\\\\\\\",\\\\n          \\\\\\\"line_ref\\\\\\\": \\\\\\\"L45\\\\\\\"\\\\n        }\\\\n      ],\\\\n      \\\\\\\"caveat\\\\\\\": \\\\\\\"An increase in PD-L1 expression can have multiple biological interpretations, and the excerpt does not provide effect sizes across all tumor models.\\\\\\\"\\\\n    },\\\\n    {\\\\n      \\\\\\\"claim_id\\\\\\\": \\\\\\\"C04\\\\\\\",\\\\n      \\\\\\\"claim\\\\\\\": \\\\\\\"Combination therapy improves tumor control in mice and is consistent with improved survival in a retrospective vaccinated human subgroup receiving ICI.\\\\\\\",\\\\n      \\\\\\\"strength\\\\\\\": \\\\\\\"tentative\\\\\\\",\\\\n      \\\\\\\"evidence\\\\\\\": [\\\\n        {\\\\n          \\\\\\\"quote\\\\\\\": \\\\\\\"Combined intervention improves tumor control in mice and aligns with better outcomes in the retrospective human cohort.\\\\\\\",\\\\n          \\\\\\\"line_ref\\\\\\\": \\\\\\\"L46\\\\\\\"\\\\n        },\\\\n        {\\\\n          \\\\\\\"quote\\\\\\\": \\\\\\\"| Retrospective human survival comparison p-value | p=0.01 | N/A | Vaccinated subgroup had improved survival under ICI treatment |\\\\\\\",\\\\n          \\\\\\\"line_ref\\\\\\\": \\\\\\\"L30\\\\\\\"\\\\n        }\\\\n      ],\\\\n      \\\\\\\"caveat\\\\\\\": \\\\\\\"The human analysis is retrospective and non-randomized; residual confounding is likely, and vaccination timing relative to ICI initiation varied across patients.\\\\\\\"\\\\n    },\\\\n    {\\\\n      \\\\\\\"claim_id\\\\\\\": \\\\\\\"C05\\\\\\\",\\\\n      \\\\\\\"claim\\\\\\\": \\\\\\\"The sensitization benefit depends on type I interferon signaling, because IFNAR1 blockade eliminates the effect.\\\\\\\",\\\\n      \\\\\\\"strength\\\\\\\": \\\\\\\"moderate\\\\\\\",\\\\n      \\\\\\\"evidence\\\\\\\": [\\\\n        {\\\\n          \\\\\\\"quote\\\\\\\": \\\\\\\"Blocking type I interferon signaling with anti-IFNAR1 eliminated the observed sensitization benefit.\\\\\\\",\\\\n          \\\\\\\"line_ref\\\\\\\": \\\\\\\"L39\\\\\\\"\\\\n        },\\\\n        {\\\\n          \\\\\\\"quote\\\\\\\": \\\\\\\"Intratumoral mRNA vaccination triggers local innate sensing and type I interferon signaling.\\\\\\\",\\\\n          \\\\\\\"line_ref\\\\\\\": \\\\\\\"L42\\\\\\\"\\\\n        }\\\\n      ],\\\\n      \\\\\\\"caveat\\\\\\\": \\\\\\\"These results are described at a summary level here, and the excerpt does not specify which tumor models or endpoints were used for the IFNAR1 perturbation.\\\\\\\" \\\\n    }\\\\n  ]\\\\n}\\\\n\\\"}\",\n  \"call_id\": \"call_jY0Py9TRZh7RYYvtdLQww0kb\",\n  \"name\": \"write_file\",\n  \"parsed_arguments\": null\n}\\n[tool-call]\\n{\n  \"id\": \"fc_078df658a1e25c9f006990724f21e0819ea277fbc9065d615e\",\n  \"type\": \"function_call\",\n  \"status\": \"completed\",\n  \"arguments\": \"{\\\"file_path\\\":\\\"output/public_summary.json\\\",\\\"content\\\":\\\"{\\\\n  \\\\\\\"headline\\\\\\\": \\\\\\\"Intratumoral mRNA vaccination may make tumors more responsive to checkpoint immunotherapy\\\\\\\",\\\\n  \\\\\\\"plain_language_summary\\\\\\\": \\\\\\\"Immune checkpoint inhibitors (ICIs) can lead to long-lasting cancer responses, but many tumors do not respond because the immune system is not strongly activated against them. This study tested the idea that delivering an mRNA vaccine directly into a tumor can create a local, interferon-driven inflammatory signal that helps the immune system notice the tumor. In mouse tumor models, the authors report that intratumoral mRNA vaccination increased signs of immune activation, including broader antigen presentation on MHC-I and higher CD8+ T-cell infiltration, and it also increased PD-L1 expression, which provides a rationale for combining the approach with anti-PD-L1 therapy. The paper also includes a retrospective analysis of 130 metastatic patients treated with ICIs, where the subgroup with prior SARS-CoV-2 mRNA vaccination (43 patients) had improved survival compared with unvaccinated patients (87), with a reported p-value of 0.01. Because the human evidence is retrospective and non-randomized, and because mouse findings do not always translate directly to people, the results support a promising hypothesis but not an immediate change in clinical practice.\\\\\\\",\\\\n  \\\\\\\"what_is_new\\\\\\\": [\\\\n    \\\\\\\"The paper links intratumoral mRNA vaccination to a stronger type I interferon state inside tumors.\\\\\\\",\\\\n    \\\\\\\"It reports broader tumor antigen display (immunopeptidome and MHC-I peptidome) after vaccination.\\\\\\\",\\\\n    \\\\\\\"It pairs preclinical combination data with a retrospective human ICI cohort stratified by vaccination status.\\\\\\\"\\\\n  ],\\\\n  \\\\\\\"why_caution_is_needed\\\\\\\": [\\\\n    \\\\\\\"The human comparison is retrospective and non-randomized, so confounding may explain some differences.\\\\\\\",\\\\n    \\\\\\\"Vaccination timing relative to ICI start varied, making it hard to infer a clear cause-and-effect relationship.\\\\\\\",\\\\n    \\\\\\\"Mouse tumor model effects may not translate directly to all human tumor types and clinical settings.\\\\\\\",\\\\n    \\\\\\\"Mechanistic readouts may be strongest in some model systems rather than consistent across all settings.\\\\\\\"\\\\n  ],\\\\n  \\\\\\\"glossary\\\\\\\": [\\\\n    {\\\\n      \\\\\\\"term\\\\\\\": \\\\\\\"mRNA vaccine\\\\\\\",\\\\n      \\\\\\\"definition\\\\\\\": \\\\\\\"A vaccine that delivers messenger RNA instructions so cells transiently make a protein that triggers immune responses.\\\\\\\"\\\\n    },\\\\n    {\\\\n      \\\\\\\"term\\\\\\\": \\\\\\\"Intratumoral\\\\\\\",\\\\n      \\\\\\\"definition\\\\\\\": \\\\\\\"Given directly into a tumor, aiming to change the local tumor environment rather than the whole body.\\\\\\\"\\\\n    },\\\\n    {\\\\n      \\\\\\\"term\\\\\\\": \\\\\\\"Immune checkpoint inhibitor (ICI)\\\\\\\",\\\\n      \\\\\\\"definition\\\\\\\": \\\\\\\"A cancer immunotherapy drug that releases inhibitory \\\\\\\"\\\\n        \\\\\\\"brakes\\\\\\\" on immune cells, helping them attack tumors.\\\\\\\"\\\\n    },\\\\n    {\\\\n      \\\\\\\"term\\\\\\\": \\\\\\\"PD-L1\\\\\\\",\\\\n      \\\\\\\"definition\\\\\\\": \\\\\\\"A protein that can suppress immune attack by engaging PD-1 on T cells; it is a common checkpoint drug target.\\\\\\\"\\\\n    },\\\\n    {\\\\n      \\\\\\\"term\\\\\\\": \\\\\\\"Type I interferon\\\\\\\",\\\\n      \\\\\\\"definition\\\\\\\": \\\\\\\"A family of immune signaling molecules that can induce antiviral-like inflammation and enhance antigen presentation.\\\\\\\"\\\\n    },\\\\n    {\\\\n      \\\\\\\"term\\\\\\\": \\\\\\\"MHC-I peptidome\\\\\\\",\\\\n      \\\\\\\"definition\\\\\\\": \\\\\\\"The set of peptides displayed on MHC class I molecules, which helps CD8+ T cells recognize abnormal cells.\\\\\\\"\\\\n    }\\\\n  ],\\\\n  \\\\\\\"open_questions\\\\\\\": [\\\\n    \\\\\\\"Would a prospective randomized clinical trial confirm a survival or response benefit when paired with ICIs?\\\\\\\",\\\\n    \\\\\\\"Which tumor types and patient subgroups are most likely to benefit from interferon-driven sensitization?\\\\\\\",\\\\n    \\\\\\\"What dosing, timing, and delivery strategies maximize efficacy while minimizing toxicity in humans?\\\\\\\",\\\\n    \\\\\\\"How general is the requirement for type I interferon signaling across different tumor microenvironments?\\\\\\\"\\\\n  ]\\\\n}\\\\n\\\"}\",\n  \"call_id\": \"call_XThxqmBj64sD15DtHdqFY2rP\",\n  \"name\": \"write_file\",\n  \"parsed_arguments\": null\n}\\n",
        "toolCalls": [
          {
            "toolName": "write_file",
            "input": {
              "file_path": "output/study_overview.json",
              "content": "{\n  \"paper\": {\n    \"title\": \"SARS-CoV-2 mRNA vaccines sensitize tumours to immune checkpoint blockade\",\n    \"doi\": \"10.1038/s41586-025-09006-8\",\n    \"publication_year\": 2025,\n    \"domain\": \"oncology-immunology\",\n    \"study_type\": \"preclinical+retrospective\"\n  },\n  \"core_question\": \"Whether intratumoral delivery of an mRNA vaccine can create an interferon-rich inflammatory state that improves sensitivity to anti-PD-L1 immune checkpoint therapy.\",\n  \"datasets_or_cohorts\": [\n    {\n      \"id\": \"mouse-efficacy-combo\",\n      \"label\": \"Mouse efficacy cohort (combination therapy)\",\n      \"sample_size_or_observations\": \"78 tumor-bearing mice\",\n      \"description\": \"Preclinical pooled mouse experiments testing intratumoral mRNA vaccine together with anti-PD-L1 combination therapy for tumor control.\" \n    },\n    {\n      \"id\": \"mouse-matched-controls\",\n      \"label\": \"Mouse control cohort (vaccine only, ICI only, vehicle)\",\n      \"sample_size_or_observations\": \"84 tumor-bearing mice\",\n      \"description\": \"Matched preclinical control arms in mice receiving vaccine-only, immune checkpoint inhibitor (ICI)-only, or vehicle control conditions.\" \n    },\n    {\n      \"id\": \"human-retrospective-metastatic\",\n      \"label\": \"Human retrospective metastatic cohort\",\n      \"sample_size_or_observations\": \"130 patients\",\n      \"description\": \"Translational retrospective cohort of metastatic patients receiving immune checkpoint inhibitor treatment, stratified by prior SARS-CoV-2 mRNA vaccination status.\" \n    },\n    {\n      \"id\": \"human-vaccinated\",\n      \"label\": \"Human vaccinated subgroup\",\n      \"sample_size_or_observations\": \"43 patients\",\n      \"description\": \"Subset of the retrospective metastatic cohort categorized as vaccinated prior to or around ICI treatment, used for survival comparison.\" \n    },\n    {\n      \"id\": \"human-unvaccinated\",\n      \"label\": \"Human unvaccinated subgroup\",\n      \"sample_size_or_observations\": \"87 patients\",\n      \"description\": \"Subset of the retrospective metastatic cohort categorized as unvaccinated, serving as the comparator group for survival under ICI treatment.\" \n    }\n  ],\n  \"major_limitations\": [\n    \"The human analysis is retrospective and non-randomized; residual confounding is likely.\",\n    \"Vaccination timing relative to ICI initiation varied across patients.\",\n    \"Tumor-type mix and treatment-history heterogeneity limit direct causal interpretation.\",\n    \"Mouse model effects may not map one-to-one to all human tumors.\",\n    \"Some mechanistic readouts were strongest in specific model systems rather than uniformly across all tested settings.\"\n  ]\n}\n"
            },
            "output": "Successfully wrote file: output/study_overview.json",
            "callId": "call_ui1P3pP99T1My6lqYKrPXxJO"
          },
          {
            "toolName": "write_file",
            "input": {
              "file_path": "output/quantitative_findings.json",
              "content": "{\n  \"findings\": [\n    {\n      \"id\": \"Q01\",\n      \"metric\": \"Fraction of tumor proteins represented in immunopeptidome\",\n      \"value\": \"62.3%\",\n      \"comparator_or_baseline\": \"37.3%\",\n      \"interpretation\": \"Intratumoral mRNA vaccination was associated with broader antigen display in the immunopeptidome.\",\n      \"evidence_line_refs\": [\"L28\"]\n    },\n    {\n      \"id\": \"Q02\",\n      \"metric\": \"Fraction of proteins represented in MHC-I peptidome\",\n      \"value\": \"40.6%\",\n      \"comparator_or_baseline\": \"20.6%\",\n      \"interpretation\": \"The MHC-I-presented peptide landscape expanded substantially after the mRNA vaccination condition.\",\n      \"evidence_line_refs\": [\"L29\"]\n    },\n    {\n      \"id\": \"Q03\",\n      \"metric\": \"Retrospective human survival comparison p-value under ICI\",\n      \"value\": \"p=0.01\",\n      \"comparator_or_baseline\": \"N/A\",\n      \"interpretation\": \"In a retrospective comparison, vaccinated patients showed improved survival while on ICI treatment.\",\n      \"evidence_line_refs\": [\"L30\"]\n    },\n    {\n      \"id\": \"Q04\",\n      \"metric\": \"Type I interferon response score (normalized units)\",\n      \"value\": \"3.1\",\n      \"comparator_or_baseline\": \"1.0\",\n      \"interpretation\": \"Tumors showed a marked induction of a type I interferon response after intratumoral mRNA vaccination.\",\n      \"evidence_line_refs\": [\"L31\"]\n    },\n    {\n      \"id\": \"Q05\",\n      \"metric\": \"PD-L1 expression fold-change in tumor tissue\",\n      \"value\": \"2.4x\",\n      \"comparator_or_baseline\": \"1.0x\",\n      \"interpretation\": \"PD-L1 pathway activity increased in tumor tissue, supporting a rationale for checkpoint blockade combination.\",\n      \"evidence_line_refs\": [\"L32\"]\n    },\n    {\n      \"id\": \"Q06\",\n      \"metric\": \"Intratumoral CD8+ T-cell density fold-change\",\n      \"value\": \"1.8x\",\n      \"comparator_or_baseline\": \"1.0x\",\n      \"interpretation\": \"Combination therapy was associated with increased CD8+ T-cell infiltration in tumors.\",\n      \"evidence_line_refs\": [\"L33\"]\n    }\n  ],\n  \"controls_or_null_results\": [\n    {\n      \"statement\": \"Vaccine-only treatment did not produce durable tumor control in non-immunogenic models.\",\n      \"evidence_line_ref\": \"L36\"\n    },\n    {\n      \"statement\": \"ICI-only treatment had limited activity in low-immunogenic baseline settings.\",\n      \"evidence_line_ref\": \"L37\"\n    },\n    {\n      \"statement\": \"Lipid particle controls lacking mRNA did not reproduce the sensitization effect.\",\n      \"evidence_line_ref\": \"L38\"\n    },\n    {\n      \"statement\": \"Blocking type I interferon signaling with anti-IFNAR1 eliminated the observed sensitization benefit.\",\n      \"evidence_line_ref\": \"L39\"\n    }\n  ]\n}\n"
            },
            "output": "Successfully wrote file: output/quantitative_findings.json",
            "callId": "call_hqLD3PYqhdoqwZ4nauoI5YW5"
          },
          {
            "toolName": "write_file",
            "input": {
              "file_path": "output/claim_audit.json",
              "content": "{\n  \"claims\": [\n    {\n      \"claim_id\": \"C01\",\n      \"claim\": \"Intratumoral mRNA vaccination induces a strong local type I interferon response in tumors.\",\n      \"strength\": \"moderate\",\n      \"evidence\": [\n        {\n          \"quote\": \"| Type I interferon response score (normalized units) | 3.1 | 1.0 | Marked induction after mRNA vaccination in tumors |\",\n          \"line_ref\": \"L31\"\n        },\n        {\n          \"quote\": \"Intratumoral mRNA vaccination triggers local innate sensing and type I interferon signaling.\",\n          \"line_ref\": \"L42\"\n        }\n      ],\n      \"caveat\": \"The report summarizes normalized scores, but does not specify timing, assay details, or variability across models in this excerpt.\"\n    },\n    {\n      \"claim_id\": \"C02\",\n      \"claim\": \"Intratumoral mRNA vaccination broadens tumor antigen presentation, including an expanded MHC-I peptidome.\",\n      \"strength\": \"moderate\",\n      \"evidence\": [\n        {\n          \"quote\": \"| Fraction of tumor proteins represented in immunopeptidome | 62.3% | 37.3% | Broader antigen display after intratumoral mRNA vaccination |\",\n          \"line_ref\": \"L28\"\n        },\n        {\n          \"quote\": \"| Fraction of proteins represented in MHC-I peptidome | 40.6% | 20.6% | Strong expansion of MHC-I-presented landscape |\",\n          \"line_ref\": \"L29\"\n        },\n        {\n          \"quote\": \"A broader peptide repertoire appears on MHC-I, improving tumor visibility to T cells.\",\n          \"line_ref\": \"L44\"\n        }\n      ],\n      \"caveat\": \"Some mechanistic readouts were strongest in specific model systems rather than uniformly across all tested settings.\"\n    },\n    {\n      \"claim_id\": \"C03\",\n      \"claim\": \"The intervention increases PD-L1 pathway activity in tumor tissue, supporting combination with checkpoint blockade.\",\n      \"strength\": \"moderate\",\n      \"evidence\": [\n        {\n          \"quote\": \"| PD-L1 expression fold-change in tumor tissue | 2.4x | 1.0x | Checkpoint axis became more targetable |\",\n          \"line_ref\": \"L32\"\n        },\n        {\n          \"quote\": \"PD-L1 pathway activity also increases, creating a rationale for combining with checkpoint blockade.\",\n          \"line_ref\": \"L45\"\n        }\n      ],\n      \"caveat\": \"An increase in PD-L1 expression can have multiple biological interpretations, and the excerpt does not provide effect sizes across all tumor models.\"\n    },\n    {\n      \"claim_id\": \"C04\",\n      \"claim\": \"Combination therapy improves tumor control in mice and is consistent with improved survival in a retrospective vaccinated human subgroup receiving ICI.\",\n      \"strength\": \"tentative\",\n      \"evidence\": [\n        {\n          \"quote\": \"Combined intervention improves tumor control in mice and aligns with better outcomes in the retrospective human cohort.\",\n          \"line_ref\": \"L46\"\n        },\n        {\n          \"quote\": \"| Retrospective human survival comparison p-value | p=0.01 | N/A | Vaccinated subgroup had improved survival under ICI treatment |\",\n          \"line_ref\": \"L30\"\n        }\n      ],\n      \"caveat\": \"The human analysis is retrospective and non-randomized; residual confounding is likely, and vaccination timing relative to ICI initiation varied across patients.\"\n    },\n    {\n      \"claim_id\": \"C05\",\n      \"claim\": \"The sensitization benefit depends on type I interferon signaling, because IFNAR1 blockade eliminates the effect.\",\n      \"strength\": \"moderate\",\n      \"evidence\": [\n        {\n          \"quote\": \"Blocking type I interferon signaling with anti-IFNAR1 eliminated the observed sensitization benefit.\",\n          \"line_ref\": \"L39\"\n        },\n        {\n          \"quote\": \"Intratumoral mRNA vaccination triggers local innate sensing and type I interferon signaling.\",\n          \"line_ref\": \"L42\"\n        }\n      ],\n      \"caveat\": \"These results are described at a summary level here, and the excerpt does not specify which tumor models or endpoints were used for the IFNAR1 perturbation.\" \n    }\n  ]\n}\n"
            },
            "output": "Successfully wrote file: output/claim_audit.json",
            "callId": "call_jY0Py9TRZh7RYYvtdLQww0kb"
          },
          {
            "toolName": "write_file",
            "input": {
              "file_path": "output/public_summary.json",
              "content": "{\n  \"headline\": \"Intratumoral mRNA vaccination may make tumors more responsive to checkpoint immunotherapy\",\n  \"plain_language_summary\": \"Immune checkpoint inhibitors (ICIs) can lead to long-lasting cancer responses, but many tumors do not respond because the immune system is not strongly activated against them. This study tested the idea that delivering an mRNA vaccine directly into a tumor can create a local, interferon-driven inflammatory signal that helps the immune system notice the tumor. In mouse tumor models, the authors report that intratumoral mRNA vaccination increased signs of immune activation, including broader antigen presentation on MHC-I and higher CD8+ T-cell infiltration, and it also increased PD-L1 expression, which provides a rationale for combining the approach with anti-PD-L1 therapy. The paper also includes a retrospective analysis of 130 metastatic patients treated with ICIs, where the subgroup with prior SARS-CoV-2 mRNA vaccination (43 patients) had improved survival compared with unvaccinated patients (87), with a reported p-value of 0.01. Because the human evidence is retrospective and non-randomized, and because mouse findings do not always translate directly to people, the results support a promising hypothesis but not an immediate change in clinical practice.\",\n  \"what_is_new\": [\n    \"The paper links intratumoral mRNA vaccination to a stronger type I interferon state inside tumors.\",\n    \"It reports broader tumor antigen display (immunopeptidome and MHC-I peptidome) after vaccination.\",\n    \"It pairs preclinical combination data with a retrospective human ICI cohort stratified by vaccination status.\"\n  ],\n  \"why_caution_is_needed\": [\n    \"The human comparison is retrospective and non-randomized, so confounding may explain some differences.\",\n    \"Vaccination timing relative to ICI start varied, making it hard to infer a clear cause-and-effect relationship.\",\n    \"Mouse tumor model effects may not translate directly to all human tumor types and clinical settings.\",\n    \"Mechanistic readouts may be strongest in some model systems rather than consistent across all settings.\"\n  ],\n  \"glossary\": [\n    {\n      \"term\": \"mRNA vaccine\",\n      \"definition\": \"A vaccine that delivers messenger RNA instructions so cells transiently make a protein that triggers immune responses.\"\n    },\n    {\n      \"term\": \"Intratumoral\",\n      \"definition\": \"Given directly into a tumor, aiming to change the local tumor environment rather than the whole body.\"\n    },\n    {\n      \"term\": \"Immune checkpoint inhibitor (ICI)\",\n      \"definition\": \"A cancer immunotherapy drug that releases inhibitory \"\n        \"brakes\" on immune cells, helping them attack tumors.\"\n    },\n    {\n      \"term\": \"PD-L1\",\n      \"definition\": \"A protein that can suppress immune attack by engaging PD-1 on T cells; it is a common checkpoint drug target.\"\n    },\n    {\n      \"term\": \"Type I interferon\",\n      \"definition\": \"A family of immune signaling molecules that can induce antiviral-like inflammation and enhance antigen presentation.\"\n    },\n    {\n      \"term\": \"MHC-I peptidome\",\n      \"definition\": \"The set of peptides displayed on MHC class I molecules, which helps CD8+ T cells recognize abnormal cells.\"\n    }\n  ],\n  \"open_questions\": [\n    \"Would a prospective randomized clinical trial confirm a survival or response benefit when paired with ICIs?\",\n    \"Which tumor types and patient subgroups are most likely to benefit from interferon-driven sensitization?\",\n    \"What dosing, timing, and delivery strategies maximize efficacy while minimizing toxicity in humans?\",\n    \"How general is the requirement for type I interferon signaling across different tumor microenvironments?\"\n  ]\n}\n"
            },
            "output": "Successfully wrote file: output/public_summary.json",
            "callId": "call_XThxqmBj64sD15DtHdqFY2rP"
          }
        ],
        "usage": {
          "promptTokens": 5976,
          "cachedTokens": 2304,
          "responseTokens": 3491,
          "thinkingTokens": 986,
          "totalTokens": 10453
        },
        "costUsd": 0.06950719999999999
      },
      {
        "step": 6,
        "modelVersion": "gpt-5.2-2025-12-11",
        "text": "[tool-call]\\n{\n  \"id\": \"fc_078df658a1e25c9f0069907257abd8819e99cecdcc7abbf90d\",\n  \"type\": \"function_call\",\n  \"status\": \"completed\",\n  \"arguments\": \"{\\\"file_path\\\":\\\"output/public_summary.json\\\",\\\"offset\\\":0,\\\"limit\\\":260}\",\n  \"call_id\": \"call_Bfld6Jq9P58zjJnCwXwq5UHt\",\n  \"name\": \"read_file\",\n  \"parsed_arguments\": null\n}\\n",
        "toolCalls": [
          {
            "toolName": "read_file",
            "input": {
              "file_path": "output/public_summary.json",
              "offset": 0,
              "limit": 260
            },
            "output": "L1: {\nL2:   \"headline\": \"Intratumoral mRNA vaccination may make tumors more responsive to checkpoint immunotherapy\",\nL3:   \"plain_language_summary\": \"Immune checkpoint inhibitors (ICIs) can lead to long-lasting cancer responses, but many tumors do not respond because the immune system is not strongly activated against them. This study tested the idea that delivering an mRNA vaccine directly into a tumor can create a local, interferon-driven inflammatory signal that helps the immune system notice the tumor. In mouse tumor models, the authors report that intratumoral mRNA vaccination increased signs of immune activa\nL4:   \"what_is_new\": [\nL5:     \"The paper links intratumoral mRNA vaccination to a stronger type I interferon state inside tumors.\",\nL6:     \"It reports broader tumor antigen display (immunopeptidome and MHC-I peptidome) after vaccination.\",\nL7:     \"It pairs preclinical combination data with a retrospective human ICI cohort stratified by vaccination status.\"\nL8:   ],\nL9:   \"why_caution_is_needed\": [\nL10:     \"The human comparison is retrospective and non-randomized, so confounding may explain some differences.\",\nL11:     \"Vaccination timing relative to ICI start varied, making it hard to infer a clear cause-and-effect relationship.\",\nL12:     \"Mouse tumor model effects may not translate directly to all human tumor types and clinical settings.\",\nL13:     \"Mechanistic readouts may be strongest in some model systems rather than consistent across all settings.\"\nL14:   ],\nL15:   \"glossary\": [\nL16:     {\nL17:       \"term\": \"mRNA vaccine\",\nL18:       \"definition\": \"A vaccine that delivers messenger RNA instructions so cells transiently make a protein that triggers immune responses.\"\nL19:     },\nL20:     {\nL21:       \"term\": \"Intratumoral\",\nL22:       \"definition\": \"Given directly into a tumor, aiming to change the local tumor environment rather than the whole body.\"\nL23:     },\nL24:     {\nL25:       \"term\": \"Immune checkpoint inhibitor (ICI)\",\nL26:       \"definition\": \"A cancer immunotherapy drug that releases inhibitory \"\nL27:         \"brakes\" on immune cells, helping them attack tumors.\"\nL28:     },\nL29:     {\nL30:       \"term\": \"PD-L1\",\nL31:       \"definition\": \"A protein that can suppress immune attack by engaging PD-1 on T cells; it is a common checkpoint drug target.\"\nL32:     },\nL33:     {\nL34:       \"term\": \"Type I interferon\",\nL35:       \"definition\": \"A family of immune signaling molecules that can induce antiviral-like inflammation and enhance antigen presentation.\"\nL36:     },\nL37:     {\nL38:       \"term\": \"MHC-I peptidome\",\nL39:       \"definition\": \"The set of peptides displayed on MHC class I molecules, which helps CD8+ T cells recognize abnormal cells.\"\nL40:     }\nL41:   ],\nL42:   \"open_questions\": [\nL43:     \"Would a prospective randomized clinical trial confirm a survival or response benefit when paired with ICIs?\",\nL44:     \"Which tumor types and patient subgroups are most likely to benefit from interferon-driven sensitization?\",\nL45:     \"What dosing, timing, and delivery strategies maximize efficacy while minimizing toxicity in humans?\",\nL46:     \"How general is the requirement for type I interferon signaling across different tumor microenvironments?\"\nL47:   ]\nL48: }",
            "callId": "call_Bfld6Jq9P58zjJnCwXwq5UHt"
          }
        ],
        "usage": {
          "promptTokens": 10529,
          "cachedTokens": 10240,
          "responseTokens": 32,
          "thinkingTokens": 205,
          "totalTokens": 10766
        },
        "costUsd": 0.005615749999999999
      },
      {
        "step": 7,
        "modelVersion": "gpt-5.2-2025-12-11",
        "text": "[tool-call]\\n{\n  \"id\": \"fc_078df658a1e25c9f0069907261092c819e92a447c22b1dd33b\",\n  \"type\": \"function_call\",\n  \"status\": \"completed\",\n  \"arguments\": \"{\\\"file_path\\\":\\\"output/study_overview.json\\\",\\\"offset\\\":0,\\\"limit\\\":120}\",\n  \"call_id\": \"call_7ewfwnhu9mK6XYh7NUzljuDt\",\n  \"name\": \"read_file\",\n  \"parsed_arguments\": null\n}\\n[tool-call]\\n{\n  \"id\": \"fc_078df658a1e25c9f0069907261093c819e96d5828c5ad17760\",\n  \"type\": \"function_call\",\n  \"status\": \"completed\",\n  \"arguments\": \"{\\\"file_path\\\":\\\"output/quantitative_findings.json\\\",\\\"offset\\\":0,\\\"limit\\\":180}\",\n  \"call_id\": \"call_tkEUnQZpXEzRKbrt1NkzGPrr\",\n  \"name\": \"read_file\",\n  \"parsed_arguments\": null\n}\\n[tool-call]\\n{\n  \"id\": \"fc_078df658a1e25c9f00699072610940819e8f6b1d4839072d39\",\n  \"type\": \"function_call\",\n  \"status\": \"completed\",\n  \"arguments\": \"{\\\"file_path\\\":\\\"output/claim_audit.json\\\",\\\"offset\\\":0,\\\"limit\\\":220}\",\n  \"call_id\": \"call_URBlfi6kEn72npHKI95E4LGW\",\n  \"name\": \"read_file\",\n  \"parsed_arguments\": null\n}\\n",
        "toolCalls": [
          {
            "toolName": "read_file",
            "input": {
              "file_path": "output/study_overview.json",
              "offset": 0,
              "limit": 120
            },
            "output": "L1: {\nL2:   \"paper\": {\nL3:     \"title\": \"SARS-CoV-2 mRNA vaccines sensitize tumours to immune checkpoint blockade\",\nL4:     \"doi\": \"10.1038/s41586-025-09006-8\",\nL5:     \"publication_year\": 2025,\nL6:     \"domain\": \"oncology-immunology\",\nL7:     \"study_type\": \"preclinical+retrospective\"\nL8:   },\nL9:   \"core_question\": \"Whether intratumoral delivery of an mRNA vaccine can create an interferon-rich inflammatory state that improves sensitivity to anti-PD-L1 immune checkpoint therapy.\",\nL10:   \"datasets_or_cohorts\": [\nL11:     {\nL12:       \"id\": \"mouse-efficacy-combo\",\nL13:       \"label\": \"Mouse efficacy cohort (combination therapy)\",\nL14:       \"sample_size_or_observations\": \"78 tumor-bearing mice\",\nL15:       \"description\": \"Preclinical pooled mouse experiments testing intratumoral mRNA vaccine together with anti-PD-L1 combination therapy for tumor control.\" \nL16:     },\nL17:     {\nL18:       \"id\": \"mouse-matched-controls\",\nL19:       \"label\": \"Mouse control cohort (vaccine only, ICI only, vehicle)\",\nL20:       \"sample_size_or_observations\": \"84 tumor-bearing mice\",\nL21:       \"description\": \"Matched preclinical control arms in mice receiving vaccine-only, immune checkpoint inhibitor (ICI)-only, or vehicle control conditions.\" \nL22:     },\nL23:     {\nL24:       \"id\": \"human-retrospective-metastatic\",\nL25:       \"label\": \"Human retrospective metastatic cohort\",\nL26:       \"sample_size_or_observations\": \"130 patients\",\nL27:       \"description\": \"Translational retrospective cohort of metastatic patients receiving immune checkpoint inhibitor treatment, stratified by prior SARS-CoV-2 mRNA vaccination status.\" \nL28:     },\nL29:     {\nL30:       \"id\": \"human-vaccinated\",\nL31:       \"label\": \"Human vaccinated subgroup\",\nL32:       \"sample_size_or_observations\": \"43 patients\",\nL33:       \"description\": \"Subset of the retrospective metastatic cohort categorized as vaccinated prior to or around ICI treatment, used for survival comparison.\" \nL34:     },\nL35:     {\nL36:       \"id\": \"human-unvaccinated\",\nL37:       \"label\": \"Human unvaccinated subgroup\",\nL38:       \"sample_size_or_observations\": \"87 patients\",\nL39:       \"description\": \"Subset of the retrospective metastatic cohort categorized as unvaccinated, serving as the comparator group for survival under ICI treatment.\" \nL40:     }\nL41:   ],\nL42:   \"major_limitations\": [\nL43:     \"The human analysis is retrospective and non-randomized; residual confounding is likely.\",\nL44:     \"Vaccination timing relative to ICI initiation varied across patients.\",\nL45:     \"Tumor-type mix and treatment-history heterogeneity limit direct causal interpretation.\",\nL46:     \"Mouse model effects may not map one-to-one to all human tumors.\",\nL47:     \"Some mechanistic readouts were strongest in specific model systems rather than uniformly across all tested settings.\"\nL48:   ]\nL49: }",
            "callId": "call_7ewfwnhu9mK6XYh7NUzljuDt"
          },
          {
            "toolName": "read_file",
            "input": {
              "file_path": "output/quantitative_findings.json",
              "offset": 0,
              "limit": 180
            },
            "output": "L1: {\nL2:   \"findings\": [\nL3:     {\nL4:       \"id\": \"Q01\",\nL5:       \"metric\": \"Fraction of tumor proteins represented in immunopeptidome\",\nL6:       \"value\": \"62.3%\",\nL7:       \"comparator_or_baseline\": \"37.3%\",\nL8:       \"interpretation\": \"Intratumoral mRNA vaccination was associated with broader antigen display in the immunopeptidome.\",\nL9:       \"evidence_line_refs\": [\"L28\"]\nL10:     },\nL11:     {\nL12:       \"id\": \"Q02\",\nL13:       \"metric\": \"Fraction of proteins represented in MHC-I peptidome\",\nL14:       \"value\": \"40.6%\",\nL15:       \"comparator_or_baseline\": \"20.6%\",\nL16:       \"interpretation\": \"The MHC-I-presented peptide landscape expanded substantially after the mRNA vaccination condition.\",\nL17:       \"evidence_line_refs\": [\"L29\"]\nL18:     },\nL19:     {\nL20:       \"id\": \"Q03\",\nL21:       \"metric\": \"Retrospective human survival comparison p-value under ICI\",\nL22:       \"value\": \"p=0.01\",\nL23:       \"comparator_or_baseline\": \"N/A\",\nL24:       \"interpretation\": \"In a retrospective comparison, vaccinated patients showed improved survival while on ICI treatment.\",\nL25:       \"evidence_line_refs\": [\"L30\"]\nL26:     },\nL27:     {\nL28:       \"id\": \"Q04\",\nL29:       \"metric\": \"Type I interferon response score (normalized units)\",\nL30:       \"value\": \"3.1\",\nL31:       \"comparator_or_baseline\": \"1.0\",\nL32:       \"interpretation\": \"Tumors showed a marked induction of a type I interferon response after intratumoral mRNA vaccination.\",\nL33:       \"evidence_line_refs\": [\"L31\"]\nL34:     },\nL35:     {\nL36:       \"id\": \"Q05\",\nL37:       \"metric\": \"PD-L1 expression fold-change in tumor tissue\",\nL38:       \"value\": \"2.4x\",\nL39:       \"comparator_or_baseline\": \"1.0x\",\nL40:       \"interpretation\": \"PD-L1 pathway activity increased in tumor tissue, supporting a rationale for checkpoint blockade combination.\",\nL41:       \"evidence_line_refs\": [\"L32\"]\nL42:     },\nL43:     {\nL44:       \"id\": \"Q06\",\nL45:       \"metric\": \"Intratumoral CD8+ T-cell density fold-change\",\nL46:       \"value\": \"1.8x\",\nL47:       \"comparator_or_baseline\": \"1.0x\",\nL48:       \"interpretation\": \"Combination therapy was associated with increased CD8+ T-cell infiltration in tumors.\",\nL49:       \"evidence_line_refs\": [\"L33\"]\nL50:     }\nL51:   ],\nL52:   \"controls_or_null_results\": [\nL53:     {\nL54:       \"statement\": \"Vaccine-only treatment did not produce durable tumor control in non-immunogenic models.\",\nL55:       \"evidence_line_ref\": \"L36\"\nL56:     },\nL57:     {\nL58:       \"statement\": \"ICI-only treatment had limited activity in low-immunogenic baseline settings.\",\nL59:       \"evidence_line_ref\": \"L37\"\nL60:     },\nL61:     {\nL62:       \"statement\": \"Lipid particle controls lacking mRNA did not reproduce the sensitization effect.\",\nL63:       \"evidence_line_ref\": \"L38\"\nL64:     },\nL65:     {\nL66:       \"statement\": \"Blocking type I interferon signaling with anti-IFNAR1 eliminated the observed sensitization benefit.\",\nL67:       \"evidence_line_ref\": \"L39\"\nL68:     }\nL69:   ]\nL70: }",
            "callId": "call_tkEUnQZpXEzRKbrt1NkzGPrr"
          },
          {
            "toolName": "read_file",
            "input": {
              "file_path": "output/claim_audit.json",
              "offset": 0,
              "limit": 220
            },
            "output": "L1: {\nL2:   \"claims\": [\nL3:     {\nL4:       \"claim_id\": \"C01\",\nL5:       \"claim\": \"Intratumoral mRNA vaccination induces a strong local type I interferon response in tumors.\",\nL6:       \"strength\": \"moderate\",\nL7:       \"evidence\": [\nL8:         {\nL9:           \"quote\": \"| Type I interferon response score (normalized units) | 3.1 | 1.0 | Marked induction after mRNA vaccination in tumors |\",\nL10:           \"line_ref\": \"L31\"\nL11:         },\nL12:         {\nL13:           \"quote\": \"Intratumoral mRNA vaccination triggers local innate sensing and type I interferon signaling.\",\nL14:           \"line_ref\": \"L42\"\nL15:         }\nL16:       ],\nL17:       \"caveat\": \"The report summarizes normalized scores, but does not specify timing, assay details, or variability across models in this excerpt.\"\nL18:     },\nL19:     {\nL20:       \"claim_id\": \"C02\",\nL21:       \"claim\": \"Intratumoral mRNA vaccination broadens tumor antigen presentation, including an expanded MHC-I peptidome.\",\nL22:       \"strength\": \"moderate\",\nL23:       \"evidence\": [\nL24:         {\nL25:           \"quote\": \"| Fraction of tumor proteins represented in immunopeptidome | 62.3% | 37.3% | Broader antigen display after intratumoral mRNA vaccination |\",\nL26:           \"line_ref\": \"L28\"\nL27:         },\nL28:         {\nL29:           \"quote\": \"| Fraction of proteins represented in MHC-I peptidome | 40.6% | 20.6% | Strong expansion of MHC-I-presented landscape |\",\nL30:           \"line_ref\": \"L29\"\nL31:         },\nL32:         {\nL33:           \"quote\": \"A broader peptide repertoire appears on MHC-I, improving tumor visibility to T cells.\",\nL34:           \"line_ref\": \"L44\"\nL35:         }\nL36:       ],\nL37:       \"caveat\": \"Some mechanistic readouts were strongest in specific model systems rather than uniformly across all tested settings.\"\nL38:     },\nL39:     {\nL40:       \"claim_id\": \"C03\",\nL41:       \"claim\": \"The intervention increases PD-L1 pathway activity in tumor tissue, supporting combination with checkpoint blockade.\",\nL42:       \"strength\": \"moderate\",\nL43:       \"evidence\": [\nL44:         {\nL45:           \"quote\": \"| PD-L1 expression fold-change in tumor tissue | 2.4x | 1.0x | Checkpoint axis became more targetable |\",\nL46:           \"line_ref\": \"L32\"\nL47:         },\nL48:         {\nL49:           \"quote\": \"PD-L1 pathway activity also increases, creating a rationale for combining with checkpoint blockade.\",\nL50:           \"line_ref\": \"L45\"\nL51:         }\nL52:       ],\nL53:       \"caveat\": \"An increase in PD-L1 expression can have multiple biological interpretations, and the excerpt does not provide effect sizes across all tumor models.\"\nL54:     },\nL55:     {\nL56:       \"claim_id\": \"C04\",\nL57:       \"claim\": \"Combination therapy improves tumor control in mice and is consistent with improved survival in a retrospective vaccinated human subgroup receiving ICI.\",\nL58:       \"strength\": \"tentative\",\nL59:       \"evidence\": [\nL60:         {\nL61:           \"quote\": \"Combined intervention improves tumor control in mice and aligns with better outcomes in the retrospective human cohort.\",\nL62:           \"line_ref\": \"L46\"\nL63:         },\nL64:         {\nL65:           \"quote\": \"| Retrospective human survival comparison p-value | p=0.01 | N/A | Vaccinated subgroup had improved survival under ICI treatment |\",\nL66:           \"line_ref\": \"L30\"\nL67:         }\nL68:       ],\nL69:       \"caveat\": \"The human analysis is retrospective and non-randomized; residual confounding is likely, and vaccination timing relative to ICI initiation varied across patients.\"\nL70:     },\nL71:     {\nL72:       \"claim_id\": \"C05\",\nL73:       \"claim\": \"The sensitization benefit depends on type I interferon signaling, because IFNAR1 blockade eliminates the effect.\",\nL74:       \"strength\": \"moderate\",\nL75:       \"evidence\": [\nL76:         {\nL77:           \"quote\": \"Blocking type I interferon signaling with anti-IFNAR1 eliminated the observed sensitization benefit.\",\nL78:           \"line_ref\": \"L39\"\nL79:         },\nL80:         {\nL81:           \"quote\": \"Intratumoral mRNA vaccination triggers local innate sensing and type I interferon signaling.\",\nL82:           \"line_ref\": \"L42\"\nL83:         }\nL84:       ],\nL85:       \"caveat\": \"These results are described at a summary level here, and the excerpt does not specify which tumor models or endpoints were used for the IFNAR1 perturbation.\" \nL86:     }\nL87:   ]\nL88: }",
            "callId": "call_URBlfi6kEn72npHKI95E4LGW"
          }
        ],
        "usage": {
          "promptTokens": 11550,
          "cachedTokens": 10624,
          "responseTokens": 107,
          "thinkingTokens": 250,
          "totalTokens": 11907
        },
        "costUsd": 0.0084777
      },
      {
        "step": 8,
        "modelVersion": "gpt-5.2-2025-12-11",
        "text": "[tool-call]\\n{\n  \"id\": \"fc_078df658a1e25c9f0069907266ca00819ebba2d9748cc68017\",\n  \"type\": \"function_call\",\n  \"status\": \"completed\",\n  \"arguments\": \"{\\\"file_path\\\":\\\"output/public_summary.json\\\",\\\"content\\\":\\\"{\\\\n  \\\\\\\"headline\\\\\\\": \\\\\\\"Intratumoral mRNA vaccination may make tumors more responsive to checkpoint immunotherapy\\\\\\\",\\\\n  \\\\\\\"plain_language_summary\\\\\\\": \\\\\\\"Immune checkpoint inhibitors (ICIs) can produce durable responses in some cancers, but many tumors do not respond because immune priming and antigen presentation are weak. This study tested whether delivering an mRNA vaccine directly into a tumor could create a local, interferon-rich inflammatory state that helps the immune system recognize the tumor and respond better to anti-PD-L1 therapy. In mouse tumor models, the report summarizes evidence for increased immune activation after intratumoral mRNA vaccination, including a broader peptide repertoire presented on MHC-I and higher intratumoral CD8+ T-cell density, alongside increased PD-L1 expression (which can make PD-L1 blockade more relevant). The paper also includes a retrospective, non-randomized analysis of metastatic patients treated with ICIs (130 total), comparing outcomes by SARS-CoV-2 mRNA vaccination status (43 vaccinated vs 87 unvaccinated). In that retrospective comparison, the vaccinated subgroup had improved survival under ICI treatment with a reported p-value of 0.01. Because the human data are retrospective and potentially confounded, and because mouse results may not translate directly to patients, the findings support a promising hypothesis but do not by themselves justify changing clinical protocols without prospective trials.\\\\\\\",\\\\n  \\\\\\\"what_is_new\\\\\\\": [\\\\n    \\\\\\\"The paper links intratumoral mRNA vaccination to a stronger type I interferon state inside tumors.\\\\\\\",\\\\n    \\\\\\\"It reports broader tumor antigen display (immunopeptidome and MHC-I peptidome) after vaccination.\\\\\\\",\\\\n    \\\\\\\"It pairs preclinical combination therapy results with a retrospective human ICI cohort stratified by vaccination status.\\\\\\\"\\\\n  ],\\\\n  \\\\\\\"why_caution_is_needed\\\\\\\": [\\\\n    \\\\\\\"The human comparison is retrospective and non-randomized, so confounding may explain some differences.\\\\\\\",\\\\n    \\\\\\\"Vaccination timing relative to ICI initiation varied across patients, complicating causal interpretation.\\\\\\\",\\\\n    \\\\\\\"Mouse model findings may not map one-to-one to all human tumors or clinical contexts.\\\\\\\",\\\\n    \\\\\\\"Some mechanistic signals may be stronger in specific model systems than across all settings tested.\\\\\\\"\\\\n  ],\\\\n  \\\\\\\"glossary\\\\\\\": [\\\\n    {\\\\n      \\\\\\\"term\\\\\\\": \\\\\\\"mRNA vaccine\\\\\\\",\\\\n      \\\\\\\"definition\\\\\\\": \\\\\\\"A vaccine that delivers messenger RNA instructions so cells transiently make a protein that can trigger immune responses.\\\\\\\"\\\\n    },\\\\n    {\\\\n      \\\\\\\"term\\\\\\\": \\\\\\\"Intratumoral\\\\\\\",\\\\n      \\\\\\\"definition\\\\\\\": \\\\\\\"Administered directly into a tumor, aiming to reshape the local tumor environment rather than the whole body.\\\\\\\"\\\\n    },\\\\n    {\\\\n      \\\\\\\"term\\\\\\\": \\\\\\\"Immune checkpoint inhibitor (ICI)\\\\\\\",\\\\n      \\\\\\\"definition\\\\\\\": \\\\\\\"A cancer immunotherapy that releases inhibitory \\\\\\\\\\\\\\\"brakes\\\\\\\\\\\\\\\" on immune cells, helping them attack tumor cells.\\\\\\\"\\\\n    },\\\\n    {\\\\n      \\\\\\\"term\\\\\\\": \\\\\\\"PD-L1\\\\\\\",\\\\n      \\\\\\\"definition\\\\\\\": \\\\\\\"A protein that can suppress immune attack by engaging PD-1 on T cells; it is a common target of checkpoint blockade drugs.\\\\\\\"\\\\n    },\\\\n    {\\\\n      \\\\\\\"term\\\\\\\": \\\\\\\"Type I interferon\\\\\\\",\\\\n      \\\\\\\"definition\\\\\\\": \\\\\\\"Immune signaling molecules that induce antiviral-like inflammation and can enhance antigen processing and presentation.\\\\\\\"\\\\n    },\\\\n    {\\\\n      \\\\\\\"term\\\\\\\": \\\\\\\"MHC-I peptidome\\\\\\\",\\\\n      \\\\\\\"definition\\\\\\\": \\\\\\\"The set of peptides displayed on MHC class I molecules, which helps CD8+ T cells detect abnormal cells.\\\\\\\"\\\\n    }\\\\n  ],\\\\n  \\\\\\\"open_questions\\\\\\\": [\\\\n    \\\\\\\"Would a prospective randomized clinical trial confirm better survival or response rates when combined with ICIs?\\\\\\\",\\\\n    \\\\\\\"Which tumor types and patient subgroups are most likely to benefit from this interferon-driven sensitization?\\\\\\\",\\\\n    \\\\\\\"What dose, schedule, and timing relative to ICI therapy would be optimal and safe in humans?\\\\\\\",\\\\n    \\\\\\\"How broadly does the requirement for type I interferon signaling apply across different tumor microenvironments?\\\\\\\"\\\\n  ]\\\\n}\\\\n\\\"}\",\n  \"call_id\": \"call_r84Xj1TcSqO4AX92X2EEDuL0\",\n  \"name\": \"write_file\",\n  \"parsed_arguments\": null\n}\\n",
        "toolCalls": [
          {
            "toolName": "write_file",
            "input": {
              "file_path": "output/public_summary.json",
              "content": "{\n  \"headline\": \"Intratumoral mRNA vaccination may make tumors more responsive to checkpoint immunotherapy\",\n  \"plain_language_summary\": \"Immune checkpoint inhibitors (ICIs) can produce durable responses in some cancers, but many tumors do not respond because immune priming and antigen presentation are weak. This study tested whether delivering an mRNA vaccine directly into a tumor could create a local, interferon-rich inflammatory state that helps the immune system recognize the tumor and respond better to anti-PD-L1 therapy. In mouse tumor models, the report summarizes evidence for increased immune activation after intratumoral mRNA vaccination, including a broader peptide repertoire presented on MHC-I and higher intratumoral CD8+ T-cell density, alongside increased PD-L1 expression (which can make PD-L1 blockade more relevant). The paper also includes a retrospective, non-randomized analysis of metastatic patients treated with ICIs (130 total), comparing outcomes by SARS-CoV-2 mRNA vaccination status (43 vaccinated vs 87 unvaccinated). In that retrospective comparison, the vaccinated subgroup had improved survival under ICI treatment with a reported p-value of 0.01. Because the human data are retrospective and potentially confounded, and because mouse results may not translate directly to patients, the findings support a promising hypothesis but do not by themselves justify changing clinical protocols without prospective trials.\",\n  \"what_is_new\": [\n    \"The paper links intratumoral mRNA vaccination to a stronger type I interferon state inside tumors.\",\n    \"It reports broader tumor antigen display (immunopeptidome and MHC-I peptidome) after vaccination.\",\n    \"It pairs preclinical combination therapy results with a retrospective human ICI cohort stratified by vaccination status.\"\n  ],\n  \"why_caution_is_needed\": [\n    \"The human comparison is retrospective and non-randomized, so confounding may explain some differences.\",\n    \"Vaccination timing relative to ICI initiation varied across patients, complicating causal interpretation.\",\n    \"Mouse model findings may not map one-to-one to all human tumors or clinical contexts.\",\n    \"Some mechanistic signals may be stronger in specific model systems than across all settings tested.\"\n  ],\n  \"glossary\": [\n    {\n      \"term\": \"mRNA vaccine\",\n      \"definition\": \"A vaccine that delivers messenger RNA instructions so cells transiently make a protein that can trigger immune responses.\"\n    },\n    {\n      \"term\": \"Intratumoral\",\n      \"definition\": \"Administered directly into a tumor, aiming to reshape the local tumor environment rather than the whole body.\"\n    },\n    {\n      \"term\": \"Immune checkpoint inhibitor (ICI)\",\n      \"definition\": \"A cancer immunotherapy that releases inhibitory \\\"brakes\\\" on immune cells, helping them attack tumor cells.\"\n    },\n    {\n      \"term\": \"PD-L1\",\n      \"definition\": \"A protein that can suppress immune attack by engaging PD-1 on T cells; it is a common target of checkpoint blockade drugs.\"\n    },\n    {\n      \"term\": \"Type I interferon\",\n      \"definition\": \"Immune signaling molecules that induce antiviral-like inflammation and can enhance antigen processing and presentation.\"\n    },\n    {\n      \"term\": \"MHC-I peptidome\",\n      \"definition\": \"The set of peptides displayed on MHC class I molecules, which helps CD8+ T cells detect abnormal cells.\"\n    }\n  ],\n  \"open_questions\": [\n    \"Would a prospective randomized clinical trial confirm better survival or response rates when combined with ICIs?\",\n    \"Which tumor types and patient subgroups are most likely to benefit from this interferon-driven sensitization?\",\n    \"What dose, schedule, and timing relative to ICI therapy would be optimal and safe in humans?\",\n    \"How broadly does the requirement for type I interferon signaling apply across different tumor microenvironments?\"\n  ]\n}\n"
            },
            "output": "Successfully wrote file: output/public_summary.json",
            "callId": "call_r84Xj1TcSqO4AX92X2EEDuL0"
          }
        ],
        "usage": {
          "promptTokens": 14745,
          "cachedTokens": 0,
          "responseTokens": 906,
          "thinkingTokens": 214,
          "totalTokens": 15865
        },
        "costUsd": 0.04148375
      },
      {
        "step": 9,
        "modelVersion": "gpt-5.2-2025-12-11",
        "text": "[tool-call]\\n{\n  \"id\": \"fc_078df658a1e25c9f0069907273891c819e9dbf943a121ccdc7\",\n  \"type\": \"function_call\",\n  \"status\": \"completed\",\n  \"arguments\": \"{\\\"file_path\\\":\\\"output/public_summary.json\\\",\\\"offset\\\":0,\\\"limit\\\":120}\",\n  \"call_id\": \"call_ZOpseoGD1i0Ue4VLcKQofL3m\",\n  \"name\": \"read_file\",\n  \"parsed_arguments\": null\n}\\n",
        "toolCalls": [
          {
            "toolName": "read_file",
            "input": {
              "file_path": "output/public_summary.json",
              "offset": 0,
              "limit": 120
            },
            "output": "L1: {\nL2:   \"headline\": \"Intratumoral mRNA vaccination may make tumors more responsive to checkpoint immunotherapy\",\nL3:   \"plain_language_summary\": \"Immune checkpoint inhibitors (ICIs) can produce durable responses in some cancers, but many tumors do not respond because immune priming and antigen presentation are weak. This study tested whether delivering an mRNA vaccine directly into a tumor could create a local, interferon-rich inflammatory state that helps the immune system recognize the tumor and respond better to anti-PD-L1 therapy. In mouse tumor models, the report summarizes evidence for increased immune a\nL4:   \"what_is_new\": [\nL5:     \"The paper links intratumoral mRNA vaccination to a stronger type I interferon state inside tumors.\",\nL6:     \"It reports broader tumor antigen display (immunopeptidome and MHC-I peptidome) after vaccination.\",\nL7:     \"It pairs preclinical combination therapy results with a retrospective human ICI cohort stratified by vaccination status.\"\nL8:   ],\nL9:   \"why_caution_is_needed\": [\nL10:     \"The human comparison is retrospective and non-randomized, so confounding may explain some differences.\",\nL11:     \"Vaccination timing relative to ICI initiation varied across patients, complicating causal interpretation.\",\nL12:     \"Mouse model findings may not map one-to-one to all human tumors or clinical contexts.\",\nL13:     \"Some mechanistic signals may be stronger in specific model systems than across all settings tested.\"\nL14:   ],\nL15:   \"glossary\": [\nL16:     {\nL17:       \"term\": \"mRNA vaccine\",\nL18:       \"definition\": \"A vaccine that delivers messenger RNA instructions so cells transiently make a protein that can trigger immune responses.\"\nL19:     },\nL20:     {\nL21:       \"term\": \"Intratumoral\",\nL22:       \"definition\": \"Administered directly into a tumor, aiming to reshape the local tumor environment rather than the whole body.\"\nL23:     },\nL24:     {\nL25:       \"term\": \"Immune checkpoint inhibitor (ICI)\",\nL26:       \"definition\": \"A cancer immunotherapy that releases inhibitory \\\"brakes\\\" on immune cells, helping them attack tumor cells.\"\nL27:     },\nL28:     {\nL29:       \"term\": \"PD-L1\",\nL30:       \"definition\": \"A protein that can suppress immune attack by engaging PD-1 on T cells; it is a common target of checkpoint blockade drugs.\"\nL31:     },\nL32:     {\nL33:       \"term\": \"Type I interferon\",\nL34:       \"definition\": \"Immune signaling molecules that induce antiviral-like inflammation and can enhance antigen processing and presentation.\"\nL35:     },\nL36:     {\nL37:       \"term\": \"MHC-I peptidome\",\nL38:       \"definition\": \"The set of peptides displayed on MHC class I molecules, which helps CD8+ T cells detect abnormal cells.\"\nL39:     }\nL40:   ],\nL41:   \"open_questions\": [\nL42:     \"Would a prospective randomized clinical trial confirm better survival or response rates when combined with ICIs?\",\nL43:     \"Which tumor types and patient subgroups are most likely to benefit from this interferon-driven sensitization?\",\nL44:     \"What dose, schedule, and timing relative to ICI therapy would be optimal and safe in humans?\",\nL45:     \"How broadly does the requirement for type I interferon signaling apply across different tumor microenvironments?\"\nL46:   ]\nL47: }",
            "callId": "call_ZOpseoGD1i0Ue4VLcKQofL3m"
          }
        ],
        "usage": {
          "promptTokens": 15884,
          "cachedTokens": 11776,
          "responseTokens": 32,
          "thinkingTokens": 15,
          "totalTokens": 15931
        },
        "costUsd": 0.0099078
      },
      {
        "step": 10,
        "modelVersion": "gpt-5.2-2025-12-11",
        "text": "[tool-call]\\n{\n  \"id\": \"fc_078df658a1e25c9f0069907290edf0819eaa36e21a309e478f\",\n  \"type\": \"function_call\",\n  \"status\": \"completed\",\n  \"arguments\": \"{\\\"pattern\\\":\\\"prospective trials\\\",\\\"dir_path\\\":\\\"output\\\",\\\"include\\\":\\\"public_summary.json\\\",\\\"exclude_pattern\\\":null,\\\"names_only\\\":false,\\\"max_matches_per_file\\\":5,\\\"total_max_matches\\\":5}\",\n  \"call_id\": \"call_KzFaZ0JC8VYiFaqfTtSLFlbb\",\n  \"name\": \"grep_search\",\n  \"parsed_arguments\": null\n}\\n",
        "toolCalls": [
          {
            "toolName": "grep_search",
            "input": {
              "pattern": "prospective trials",
              "dir_path": "output",
              "include": "public_summary.json",
              "exclude_pattern": null,
              "names_only": false,
              "max_matches_per_file": 5,
              "total_max_matches": 5
            },
            "output": "output/public_summary.json:3:  \"plain_language_summary\": \"Immune checkpoint inhibitors (ICIs) can produce durable responses in some cancers, but many tumors do not respond because immune priming and antigen presentation are weak. This study tested whether delivering an mRNA vaccine directly into a tumor could create a local, interferon-rich inflammatory state that helps the immune system recognize the tumor and respond better to anti-PD-L1 therapy. In mouse tumor models, the report summarizes evidence for increased immune activation after intratumoral mRNA vaccination, including a broader peptide repertoire presented on MHC-I and higher intratumoral CD8+ T-cell density, alongside increased PD-L1 expression (which can make PD-L1 blockade more relevant). The paper also includes a retrospective, non-randomized analysis of metastatic patients treated with ICIs (130 total), comparing outcomes by SARS-CoV-2 mRNA vaccination status (43 vaccinated vs 87 unvaccinated). In that retrospective comparison, the vaccinated subgroup had improved survival under ICI treatment with a reported p-value of 0.01. Because the human data are retrospective and potentially confounded, and because mouse results may not translate directly to patients, the findings support a promising hypothesis but do not by themselves justify changing clinical protocols without prospective trials.\",",
            "callId": "call_KzFaZ0JC8VYiFaqfTtSLFlbb"
          }
        ],
        "usage": {
          "promptTokens": 16716,
          "cachedTokens": 15744,
          "responseTokens": 57,
          "thinkingTokens": 1164,
          "totalTokens": 17937
        },
        "costUsd": 0.0215502
      },
      {
        "step": 11,
        "modelVersion": "gpt-5.2-2025-12-11",
        "text": "- [x] `output/study_overview.json`\n- [x] `output/quantitative_findings.json`\n- [x] `output/claim_audit.json`\n- [x] `output/public_summary.json`",
        "toolCalls": [],
        "usage": {
          "promptTokens": 18209,
          "cachedTokens": 5760,
          "responseTokens": 53,
          "thinkingTokens": 288,
          "totalTokens": 18550
        },
        "costUsd": 0.02756775
      }
    ],
    "totalCostUsd": 0.2109681
  }
}
